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liThe heart of creatures is the foundation of life, the Prince of all, the sun of their 
microcosm, from where all vigour and strength does flow" 
William Harvey 
Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus 
1628 
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Abstract 
Non-ischaemic right ventricular dysfunction and cardiac failure is a source of 
considerable morbidity in children with congenital heart disease. Despite an 
increasing body of evidence suggesting that the intrinsic regenerative capacity 
of the heart can be encouraged by stimulation of resident cardiac stem cells or 
the transplantation of extracardiac progenitor cells, cell transplantation has not 
previously been studied in the paediatric setting where enhancing the function 
of the ventricle in response to supraphysiological workloads might be beneficial. 
Firstly I studied extra-cellular matrix composition, myocyte homeostasis and 
gene expression in right ventricular biopsies obtained from patients with 
Hypoplastic Left Heart Syndrome (HLHS) undergoing neonatal surgical 
palliation and from patients undergoing neonatal truncus arteriosus repair in 
order to investigate potential differences in the myocardial substrate which 
could have implications for adaptive growth potential and haemodynamic 
performance in HLHS. 
Simultaneous to these activities, I collected, isolated and analysed umbilical 
cord blood stem cells from children born with either structurally-normal hearts or 
HLHS to investigate whether such cell populations might be useful in cardiac 
augmentation. 
We then transplanted human cord blood stem cells from normal cord blood 
donors into an immunosuppressed neonatal sheep model of right ventricular 
training, taking load-independent functional measurements at baseline and 
again after one month. 
III 
Transplanted human cells were detected in the myocardium, spleen, kidney and 
bone marrow up to 6 weeks after transplantation. Human cells expressed the 
haematopoietic marker CD45 and in the bone marrow and spleen, also the 
mature B cell marker CD23. Significant functional improvements were seen in 
the group receiving human cord blood stem cells compared to placebo. Data 
demonstrated that lineage negative-enriched cord blood stem cells engraft and 
adopt traditional haematopoietic cell fates in both myocardium as well as natural 
niches such as bone marrow and spleen. 
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1.0 Background 
1.1 Contemporary challenges in human congenital heart disease 
Congenital heart disease affects 1 in 125 children and is the leading non-
infectious cause of death in children. 
One of the most therapeutically challenging cardiac defects is hypoplastic left 
heart syndrome (HLHS) in which left-sided cardiac underdevelopment co-
exists with aortic hypoplasia 1• Considered uniformly lethal until 1980, it 
composes 7 to 9% of neonatal congenital heart disease and is responsible 
for 25% of cardiac deaths in the first week of life. Untreated, most children 
die within a month of birth. The principal surgical treatment offered to parents 
consists of repair over three stages performed at approximately 1 week, 3 
months and 2 years of age respectively, culminating in a univentricular 
circulation in which the morphological right ventricle supports the systemic 
circulation whilst blood returns passively to the lungs via a Fontan circuit. 
The enormous improvement in survival for the 1 st stage procedure since it 
was first described by Norwood2 in the 1980s ranks amongst the greatest 
achievements in congenital cardiac surgery in the past 20 years. However, 
despite advances in surgical technique and intensive care3-S, there remains a 
persistent and frustrating 5-15% risk of sudden death before the 2nd stage 
can be completed. Contributing factors include the presence of inefficient 
parallel circulations in this period combined with the inherently inferior 
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pumping capability of the morphological right ventricle. Later on in life there is 
a steady attrition attributable to the long-term complications of a Fontan 
circulation. 
It is now increasingly apparent that several congenital heart defects once 
attributed to multifactorial aetiologies are actually due to mutations or defects 
in developmental control genes, transcriptional programs and cell signalling. 
Greater insight into normal cardiac development and the understanding of 
congenital heart disease has the potential for impacts on human disease in 
several ways. The identification of cardiac control genes and their associated 
transcription factors in both health and disease6•s could be exploited to 
design therapies for the improvement or prevention of congenital heart 
defects. The involvement of developmental control mechanisms in the 
pathogenesis of adult heart disease also indicates therapeutic potential of 
such strategies. 
Already a number of novel haemodynamic therapeutic strategies 
concentrating on improving epigenetic factors for cardiac development, such 
as hydraulic flow9,1o, have been developed. For example, the attempts to 
modulate the natural history of congenital aortic valve stenosis to a more 
favourable one by fetal aortic balloon valvuloplasty.11 
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1.2 Cardiac developmental biology 
The heart is the first organ to form in the embryo and all subsequent events 
in the development of the organism depend on its function (figure 1.2.1). 
Inherited mutations in cardiac regulatory genes give rise to congenital heart 
disease, the commonest form of human birth defect, affecting 1 in 125 live 
births and their frequency in spontaneously aborted pregnancies is estimated 
to be ten times higher.12 From initial morphological foundations, work has 
evolved through physiological and functional studies towards gaining a 
greater appreciation at genetic and molecular levels. Together, the increased 
insight this affords has provided new therapeutic approaches for prevention 
and palliation of cardiac disease. 
Figure 1.2.1: Synopsis of cardiac development 
Clrdlec: 
cushions 
looping 
heart tube 
Cardlec: 
cushions 
Purltlnje f1bera 
Reproduced with permission from Olson EN Nature Medicine 2004; 10:467 
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1.2.1 Heart Development & Congenital Heart Disease 
The initial commitment of mesodermal progenitor cells to a cardiac fate is 
dependent on signalling between adjacent tissues. Members of bone 
morphogenetic protein (BMP) family have positive roles and wingless 
proteins have positive and negative roles in establishment of the cardiac 
Iineage13-16. Entry and maintenance of cells into the cardiac lineage in 
response to appropriate signals is coupled to expression of transcription 
factors that initiate the program for cardiac gene expression and drives the 
morphogeneic events involved in formation of the multi-chambered heart. 
It was not until the early 1990s that the genetic underpinnings of cardiac 
morphogenesis began to emerge. In particular, the discovery of the 
homeobox gene tinman (tin), required the formation of the primitive heart in 
the fruit fly Drosophila melanogaster. 17,18 A mammalian ortholog of tinman 
called Nkx2.S or Csx, is expressed in cardiac muscle cells from the onset of 
embryonic heart formation until adulthood6,19. Although highly conserved and 
restricted to the cardiac lineage, Nkx2.S is dispensable for establishment of 
the cardiac lineage. Instead, knock-out mice lacking Nkx2.S die during mid-
embryogenesis from abnormalities of growth and development of the left 
ventricle20 which suggests that Nkx2.S serves a different, albeit related, 
function than tinman or that other genes have redundant functions the 
specification and subsequent development of cardiac cell fate. 
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In contrast to skeletal muscle, in which a single transcription factor MyoD is 
sufficient to activate the full program of muscle differentiation, cardiac muscle 
depends on a combination of transcription factors. In mammals as well as 
fruit flies, the MADS-box factor myocyte enhancer factor-2 (MEF-2), in 
concert with other transcription factors, directly activates the expression of 
genes encoding myofibrillar proteins.21 ,22Ukewise, serum response factor 
(SRF), a related MADS-box factor, associates with an array of transcription 
factors including Nkx2.S, GATA4 and myocardin to control the expression of 
muscle structural genes whose products such as actin, myosin and 
troponins23,24are incorporated into the contractile apparatus. The 
homeodomain protein Irx4 also activates ventricular genes whilst 
suppressing atrial genes in the ventricular chambers25. Analysis of regulatory 
DNA sequences responsible for cardiac transcription revealed a complex 
regulation whereby individual genes are often controlled by multiple, 
independent enhancers that direct expression in highly regionally-restricted 
patterns in the developing heart26• Cardiac transcription factors, in addition to 
activating subordinate genes involved in cardiac function, also amplify and 
maintain their expression within mutually-reinforcing transcriptional circuits 
involving positive feedback loops and protein-protein interactions. 
Two populations of cardiac progenitors termed primary and seconday heart 
fields contribute to the developing heart in vertebrates27, Cardiac myocytes 
are organised into a linear tube that then undergoes right-ward looping in 
response to an axial signalling system that establishes asymmetry across the 
left-right axis of the embry028. Subsequent balloon-like growth of the looped 
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heart tube and septation gives rise to the multichambered heart. The right 
and left ventricular and atrial chambers of the heart each have distinct 
functions and are separated by interatrial and interventricular septae so blood 
can be delivered to the lungs and thence the body, in series. 
Examples of congenital heart disease in which one ventricle is 
underdeveloped, for example hypoplastic left heart syndrome or pulmonary 
atresia with intact ventricular septum, may suggest that the two ventricles 
might form independently according to mutually exclusive growth programs in 
regionally distinct areas in the embryologic heart tube. Insight into the genetic 
circuitry of ventricular development was provided by the discovery of two 
chamber-restricted basic helix-loop-helix transcription factors, HAND1 and 
HAND2, that are expressed in left and right ventricles, respectively29. 
Knockout mice lacking HAND2 do not form a right ventricle and mice lacking 
both genes form neither ventricle30• These mice were the first to demonstrate 
that a single gene mutation could result in the ablation of an entire segment 
of the heart and therefore supported the concept that the heart is assembled 
in a modular fashion with each compartment governed by unique genetic 
programs. The segmental pattern of heart development is also exemplified by 
the phenotype of mice lacking the homeobox gene /s/1, in which entire 
regions of the heart may be absent31 • Mutations in other cardiac control 
genes in mice and zebrafish further substantiate such a model32• 
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Further growth and maturation of cardiac myocytes within the developing 
ventricular chambers depends on the interplay of signalling events between 
adjacent cell layers and epigenetic factors such as flow and shear stress 
10,33. Signalling by neuregulins from the endocardium, a thin layer of cells 
lining the cardiac chambers, to the ErbB receptor in the myocardium is 
required for growth of the mesocardium/ventricular layef4. Mutations that 
alter this signalling interaction result in thin-walled myocardium and 
embryonic death. Interference with neuregulin signalling in the adult heart by 
antibodies to ErbB, as used in breast cancer therapy, can also lead to 
contractile dysfunction35. The epicardium also provides a rich source of 
signals stimulating cardiac growth, for example retinoic acid and peptide 
growth factors36. 
Heart valve formation requires signalling from the myocardium to localised 
swellings of the endocardium known as cardiac cushions and occurs by TGF-
B family members. Disruption of this mechanism in knockout mice lacking 
cardiac expression of BMPs or BMP receptors result in valve abnormalities 
and VSDs which account for a majority of congenital heart defects37,38. 
Neural crest cells from the pharyngeal arches also populate the developing 
heart and are important in the formation of valves, interventricular septum 
and patterning of the outflow tract and great arteries39,40. 
Each cardiac cycle of contraction and relaxation is controlled and propagated 
throughout the heart by specialised conduction tissue and by direct cell-cell 
coupling of cardiac myocytes. Until recently, the embryonic origins of the cell 
lineages that form the cardiac conduction system were unclear; it has now 
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been demonstrated that Purkinje cells are derived from a subpopulation of 
ventricular cardiomyocytes in response to signalling by endothelin-1 and 
neuregulins41 ,42. Fate mapping of cardiac conduction lineages in mice has 
yielded insights into the transcriptional pathways responsible for the 
formation of this specialised cardiac structure and the molecular basis for 
cardiac conduction defects43• 
Mutations in cardiac transcription factors, their regulatory genes and the 
genes they in turn regulate, have been identified in humans with congenital 
heart diease7,44-46. Humans and mice heterozygous for missense mutations 
in Nkx2.S show a spectrum of structural and functional defects including 
atrial-septal and ventricular-septal anomalies and conduction defects47. The 
molecular basis for these defects is unclear but it may be that subtle defects 
in growth of patterning of cardiac myocytes during embryogenesis occur. 
Holt-Oram syndrome, characterised by heart and limb defects, has been 
attributed to mutations in the T -box gene TBXS. Missense mutations in 
GATA4 that impair its interaction with TBXS have also been shown to cause 
VSDs in humans48. Despite such descriptions of abnormal cardiac 
phenotypes, important gaps in our understanding of developmental control 
mechanisms remain. Relatively few target genes regulated by cardiac 
transcription factors have been identified and how they ultimately relate to 
cardiac malformations is unclear. It must be considered that most of the 
conclusions regarding the functions of cardiac control genes have been 
based on phenotypes resulting from homozygous gene deletion in model 
organisms, whereas most mutations in humans producing survivable 
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disease, are heterozygous. Congenital heart defects in human also show 
remarkable variability in penetrance and expressivity, indicative of modifier 
genes and environmental influences in determining disease phenotypes. 
Much remains to be learned about the identities and mechanisms of action of 
such modifiers. 
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1.3 The morphological right ventricle 
Anatomy 
The normal morphological right ventricle lies anteriorly in the chest, is 
wrapped around the left ventricle and has a geometrically complex shape 
unlike the ellipsoid shape of the left ventricle which is more conical in shape 
and has a wall thickness 3 to 4 times greater than the RV free wall. RV 
trabeculations are coarse compared to the finely trabeculated left ventricle 
and the RV outflow tract is muscular and elongated (figure 2). These 
differences in ventricular morphology reflect differences in genetically-
determined developmental patterning and their differing physiological roles. 
Figure 1.3.1: Endocast of heart showing cardiac chambers and great 
vessels: RA, right atrium; RV, right ventricle; LV, left ventricle; Ao, aorta; PT, 
main pulmonary artery/pulmonary trunk 
Ho, S. et al. Heart 2001 ;86:3ii-11 ii 
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Physiology 
Once considered haemodynamically unimportant49 and essentially a conduit 
to the pulmonary circulation, the right ventricle actually performs several 
essential functions: 
Maintain adequate pulmonary perfusion pressure under varying 
circulatory and loading conditions in order to deliver desaturated 
venous blood to the membranes of the lungs for gas exchange 
Maintain a low systemic venous pressure to prevent tissue and organ 
congestion 
Although there is some beat-to-beat variability, in the absence of shunting, 
the average stroke volume of left and right ventricles must be equal. The 
normal right ventricle has a lower ejection fraction than the left, consequently 
its end diastolic volume is a little larger. The contractile mechanics by which 
blood is ejected from the right ventricle differs compared to the left ventricle 
whose pressure-volume relationship shows an efficient square wave pump 
with well-defined period of isovolumic contraction, ejection, relaxation and 
diastolic filling. In the normal right ventricle with normal pulmonary vascular 
resistance, the ejection phase is markedly different to the left ventricle. 
Ejection from the RV begins early in the rise in pressure, often with a poorly 
defined period of isovolumic contraction. Equally important, ejection 
continues after right ventricular pressure has peaked; indeed up to 50% of 
the stroke volume is ejected during the decline in RV pressure, a period that 
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can last as long as BOms. Although variable, the right ventricular isovolumic 
relaxation period may also be poorly defined. Although the cyclical efficiency 
is low, the energy efficiency is high. 
Right ventricular function may be impaired by primary right-sided heart 
disease, or secondary to left-sided cardiomyopathy or valvular disease5o. 
Right ventricular dysfunction may likewise affect left ventricular function, not 
only by limiting left ventricular preload, but also by adverse systolic and 
diastolic interaction via the interventricular septum and the pericardium, a 
well-characterised phenomenon known as ventricular interdependence.51 
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1.4 Functional assessment of the right ventricle 
Although LV function and dysfunction and its relationship to clinical prognosis 
has been studied extensively, the role of RV morphology and its function in 
cardiovascular disease has not until recently attracted a similar degree of 
interest, largely due to the fact that the majority of clinical workload 
comprises of acquired cardiovascular disease predominantly affecting the left 
ventricle. 
Any form of RV assessment is hampered by load-dependent changes in 
geometry, the unusual physiology ejection reflecting low pulmonary vascular 
resistance, ventricular interaction and the effect of respiration, to which 
congenital abnormalities of size, position and structure that may be 
superimposed. An appreciation of RV function is however essential in the 
management of congenital heart disease which is of increasingly relevance 
to clinical practice. Many patients have become adolescents and adults 
thanks to the major advances of paediatric cardiology and cardiac surgery in 
the latter half of the 20th century. In particular. there are a substantial number 
of patients with single-ventricle physiology. systemic right ventricles (RVs). or 
complex intracardiac baffles who are now entering adult life, creating a 
patient population in whom the RV is often a key prognostic facto,.s2. 
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In everyday practice, clinicians largely rely on non-invasive two-dimensional 
echocardiography supplemented by alternative techniques including tissue 
Doppler imaging, three dimensional echocardiography, cardiac magnetic 
resonance imaging and invasive assessment with pressure-volume loops, 
which permit accurate assessment of RV volume, mass and function.53-59 
Pressure-volume loops 
Analysis of RV function by pressure-volume loops is attractive because it 
simultaneously quantifies key determinants of ventricular function in a 
relatively independent fashion.50,51 Conventional indices such as end-systolic 
and end-diastolic pressures and volumes, stroke volume, stroke work and 
ejection fraction can be directly derived from the loops (Figure 1.4.1). 
Differentiation of the volume signal (dV/dt) yields RV inflow and outflow 
signals, from which early and late filling rates and ejection rate can be 
obtained. Analysis of the pressure decay during relaxation yields the 
relaxation time constant tau, whereas differentiation of the pressure signal 
yields dP/dtMIN and dP/dtMAx. Whilst revealing important information on 
systoliC and diastolic right ventricular function, these however also reflect 
prevailing loading conditions. 
Pressure-volume relations, which may be derived from pressure-volume 
loops collected during a loading intervention, provide indices of right 
ventricular systolic and diastolic function largely independent of loading 
conditions and therefore better reflect intrinsic myocardial function. The 
position and slope (end systolic elastance) of the end systoliC pressure-
volume relation are sensitive indicators of right ventricular systoliC function. 
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Additional systolic indices include the slope of the relation between stroke 
work and end diastolic volume, the preload recruitable stroke work (PRSW), 
and the slope of the relation between dP/dtMAx and end diastolic volume 
(dPdt-EDV).62 
Figure 1.4.1: Steady state pressure-volume loops obtained from an adult 
sheep 
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Diastolic function may be derived from the end diastolic pressure-volume 
points. The slope of this relation represents diastolic stiffness or diastolic 
compliance (1/stiffness). When obtained over a wider range, the end diastolic 
pressure-volume relation is generally non-linear and better approximated by 
an exponential fit, such as: 
EDP = A-exp(k·EDV) where k is the diastolic stiffness constant.63 
Construction of pressure-volume relations requires pressure and volume 
data obtained during various loading conditions, preferably induced by rapid, 
mechanical interventions that minimally disturb intrinsic myocardial function. 
This can be achieved by temporary occlusion of the inferior vena caval inflow 
either with an endoluminal balloon or direct occlusion at open surgery. The 
conductance catheter is the most commonly used experimental instrument to 
acquire ventricular pressure-volume loops. The catheter contains a high 
fidelity pressure sensor and electrodes to measure right ventricular electrical 
conductance from which instantaneous ventricular cavity volume can be 
determined.64 Pressure-volume loop analysis is regarded as the optimal way 
to quantify RV function, has been widely used in experimental animal 
studies65-68 and although validated and used in humans,69-71 its clinical use is 
hampered by its invasive nature, cumbersome logistics and sterilisation 
issues of the expensive, fragile catheters. 
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Alternative methods have been proposed that could provide estimates of 
systolic pressure-volume relationships based on steady state and single-
beat data which whilst conceptually attractive by obviating the need for a 
loading intervention, their accuracy remains to be determined.72 
17 
1.5 Stem Cells 
Stem cells are defined by their capacity for self-renewal, transformation into 
dedicated progenitor cells and differentiation into specialised progeny?3,74 
They can be further classified by morphological and functional criteria or by 
their surface markers. Their discovery and importance to science in general 
is potentially great, offering a tool to help unravel early molecular events in 
organ development or disease and potentially therapeutic hope for patients 
requiring repair or replacement of damaged, degenerative or genetically-
deficient tissues and organs. 
1.5.1 Current status of cardiovascular cell therapy 
The possibility of using stem cells in the repair, regeneration or repopulation 
of damaged or diseased adult tissue has prompted cardiovascular 
researchers to engage in innovative work to explore ways in which cardiac 
function may be improved. 
In the developed world, contemporary management of acute cardiovascular 
events such as acute myocardial infarction (AMI), thrombotic cerebral 
infarction and peripheral arterial disease has reduced mortality but increased 
overall morbidity. Chronic heart failure has emerged as a major worldwide 
epidemic and has experienced a shift in aetiology towards long-term 
survivors of myocardial infarction as opposed to hypertension or valvular 
disease.75 Owing to this burden of disease, research work to date has 
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necessarily been focussed on improving left ventricular function in chronic 
ischaemic heart disease by stem cell transplantation. Other work has 
explored the production of tissue-engineered vascular conduits and valves 
using related cell culture and matrix scaffold techniques?6-78 
1.5.2 Cardiac homeostasis 
The long-standing dogma of heart development, one of a terminally-
differentiated organ incapable of self-renewal or regeneration, has recently 
been challenged. Low levels of myocyte proliferation compared to other 
tissues such as liver, was previously taken to mean that the post-natal heart 
could only react to increases in physiological workload through hypertrophy 
as opposed to hyperplasia. Difficulties in identifying mitotic figures or DNA 
synthesis within myocytes further reinforced the notion that the heart 
functions throughout life with the same terminally-differentiated cells.79 Yet 
the only way this paradigm could be realised would be if cardiac myocytes 
were somehow immortal or otherwise exempt from the normal ageing 
process affecting the rest of the body. 
Ventricular dysfunction was thought to intervene once the heart's 
hypertrophic capabilities were exhausted and the effects of myocardial 
infarction irreversible with any observed recovery of ventricular function 
attributed to hypertrophic and fibrosis remodelling. 
Dispelling these myths has stimulated the clarification of myocardial 
homeostatic mechanisms that might then be exploited in an attempt to 
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favourably modulate clinically-relevant human disease processes. A 
therefore more rational explanation is that the heart, in keeping with other 
organs, experiences both cell growth and death and that the balance of these 
two processes achieves myocardial cell homeostasis, determining the overall 
functional efficacy of the organ and the survival of the organism as a whole. 
Any imbalance between cell growth and death in pathophysiological states 
might result in decompensation, overt heart failure and eventual death. 
1.5.3 Evidence of post-natal myocardial proliferation and chimerism In 
sOlid-organ transplantation 
Irrespective of causation, cardiac failure has several common effector 
pathways including depressed contractility due to altered expression and 
function of calcium handling proteins and other sarcomeric proteins and 
enzymes, the development of interstitial fibrosis and a net loss of myocytes 
further reducing ventricular function. This has been borne out by studies of 
myocytes from patients dying from heart failure in whom a 10 to 60 fold 
increase in mitotic figures was noted,80 albeit in a small and insignificant 
proportion of myocytes probably insufficient as an isolated, robust repair 
mechanism, but evidence of reparative intent at the very least. These 
concepts are supported by recent work suggesting large numbers of mitotic 
figures in adult hearts with aortic stenosis.80.81 The discovery of male 
recipient cells in transplanted female donor hearts82 raised the possibility that 
male cells colonised the donor heart, creating a chimera and differentiated 
into myocytes and blood vessels, a process consistent with the hypothesis 
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that extra-cardiac stem cell-like cells may migrate to a cardiac allograft and 
give rise to organ-specific progenies. 
1.5.4 Resident cardiac stem cells 
Although primarily comprised of terminally differentiated post-mitotic effector 
cells, many tissues retain smaller populations of stem cells capable of slowly 
replenishing cells that are lost through wear and tear, injury, and disease. An 
emerging body of evidence, including the isolation of stem cells from several 
different somatically-derived tissues and organs83-86, suggests that the 
homeostatic maintenance of most tissues is ultimately mediated by such 
tissue- or organ-specific stem cells that have the ability to self-perpetuate 
through a process known as self-renewal, in addition to being capable of 
giving rise to mature effector cell types in a sustained manner through 
differentiation. 
The existence, origin and migratory properties of such dividing cells capable 
of attempts at cardiac renewal remains controversial. Possible sources 
include the bone marrow from where cells may be released as part of an 
ongoing process of renewal and also in response to injury. Others favour the 
existence of a local "resident" cardiac stem cell population, a theory 
supported by the isolation of cells expressing a progenitor (lin-, c-Kit+ and 
Sca-1 +) phenotype.87 The epicardium has also been postulated to harbour a 
subset of progenitor cell that migrates in the myocardium, differentiating into 
myocardial or vascular components.88 
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Akin to the brain, the heart seems to have reservoirs of progenitor cells that 
may not be sufficient to replace the acute loss of a large number of cells, but 
may be able to replace a slow apoptotic loss of cells over a lifetime. The 
presence of these cell populations, known as resident cardiac stem cells 
(CSC), capable of differentiating into cardiomyocyte or vascular lineages 
suggests that these cells could be used for cardiac tissue repair or a 
molecular target for stimulation. 
The above concepts concerning cardiac regeneration may be unpalatable for 
some, but doubters need only look elsewhere in the animal kingdom where 
self-renewal is a well recognised phenomenon. Cardiac regeneration is well 
recognised in certain organisms such as the Urodeles species of amphibian89 
and zebrafish,90 in whom total replacement of an amputated Iimb,91 fin, or tail 
can also be achieved via production of an undifferentiated cell mass called 
the blastema. These are processes demanding dedifferentiation and 
transdifferentiation, therefore providing a practical demonstration of adult 
stem cell plasticity. 
Traditionally, tissue-resident adult stem cells were believed only able to 
differentiate into progeny within tissue lineage boundaries. Plasticity implies 
that stem cells can transdifferentiate into mature cell types outside their 
original lineage in response to microenvironmental cues. For example, 
haematopoietic stem cells (HSCs) may transdifferentiate into cardiomyocytes 
and blood vessels when transplanted into murine myocardium92. 
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These dramatic examples of restorative growth may be dependent on 
retained proliferative potential in a subset of adult cardiomyocytes kept in 
check under normal circumstances; the existence of such endogenous repair 
mechanisms suggests that cardiac repair might also be realised 
therapeutically in the clinical setting. Other mechanisms that could aid this 
process include: 
• Overriding cell cycle checkpoints that constrain a reactive proliferation 
of ventricular myocytes 
• Supplementing endogeneous cytoprotective mechanisms, or inhibiting 
cell death pathways 
• Supplementing angiogenic mechanisms using growth factors or 
vessel-forming cells 
• Provision of exogenous non-cardiac cells as surrogates or precursors 
for cardiac muscle. 
Simultaneous to investigations of bone-marrow stem cell plasticity, searches 
for resident cardiac stem cells took place. Unlike the proposal that bone 
marrow serves as a reservoir for cells that can differentiate into myocardium 
when placed in the milieu of the injured heart, this hypothesis was in keeping 
with the basic tenet of developmental biology that stem cells reside in the 
tissue that they repair. 
Contributors to the earlier landmark study by Orlic et al,92 published a report 
in 2003 describing the isolation of adult cardiac stem cells from rat 
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myocardium. In the latter study, Beltrami et aLisolated a self-renewing 
clonogenic population of Lin-c-kit+ cells from normal rat myocardium93• In 
vitro, these cells gave rise to cells with characteristics of myocytes, smooth 
muscle cells and endothelial cells. In vivo, implantation of 1 x1 05 of these cells 
into post-infarcted myocardium resulted in decreased infarct size, myocardial 
regeneration and preservation of cardiac function. The authors presented 
several lines of evidence to argue against cell fusion as a mechanism for 
myocardial regeneration. Finally, although they could not conclude whether 
these supposedly cardiac stem cells originally reached the myocardium 
through the circulation, they found no cells with similar characteristics in the 
bone marrow or peripheral circulation. A significant limitation of this study is 
that the techniques used to identify cardiac regeneration are the same as 
those used in the earlier study by Orlic et al.92 which have been questioned 
as several other groups have been unable to reproduce the results94-96• 
Oh et al.97 also reported the existence of adult heart-derived cardiac 
progenitor cells in mice. Unlike Beltrami et a1.93, these cells are Lin-c-kit-Sca-
,+; in vitro, 5-azacytidine can induce cardiac differentiation of these cells. 
Moreover, in vivo, these cells can differentiate into myocytes when delivered 
into the infarct border-zone, with approximately half of these representing 
fusion products between native myocytes and the donor Lin-c-kirSca-l+ stem 
cells. 
Some of Beltrami's co-workers also reported the discovery of clusters of stem 
cells in the left ventricular outflow tract transitioning to cardiomyocytes, in 
patients undergoing aortic valve replacement for aortic stenosis 98. These 
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cells were c-kit+Sca-1 +, and some co-expressed cardiomycyte markers 
GATA-4 and MEF2. They suggest that the presence of these cells strongly 
supports the existence of cardiac stem cells in humans. Messina et al,99 
performed studies in both mice and humans, isolating self-renewing 
clonogenic cells that grow as self-adherent clusters ('cardiospheres') in vitro 
and express the stem cell markers c-kit, CO-34 and Sca-1. These cells 
become beating cardiomyocytes when co-cultured with postnatal rat 
cardiomyocytes and can contribute to myocardium in vivo when injected into 
post-infarcted border-zone myocardium. 
More recently, Laugwitz et al. described the isolation of cardiac progenitors 
from the heart of the postnatal rat, mouse and human which carry the genetic 
marker isl1; these cells can adopt a fully differentiated cardiomyocyte 
phenotype in vitro in the absence of cell fusion10o• 
Putting this work in perspective, there is emerging evidence that resident 
cardiac stem cells may exist in murine and human organ models. It is 
possible that different groups of cardiac stem cells have been isolated by 
different researchers; for example Beltrami et al.'s are c-kit+, whereas those 
of Oh et al. are c-kit-. Well-conceived mechanistic studies are now needed to 
more fully understand the nature of resident cardiac stem cells. 
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1.5.5 Could resident cardiac stem cells be subject to therapeutic 
supplementation or manipulation? 
With early studies supporting the notion that adult cardiac regeneration 
occurs naturally, albeit at low levels, several key questions arise as to which 
cells might participate in myocardial regeneration? Is the concept of resident 
cardiac stem cells irrefutable? Or do non-cardiac stem cells contribute to 
myocardial regeneration? 
Intriguingly, CSCs can be clonally expand from human myocardial biopsies. It 
has been reported that intramyocardial injection of these cells after AMI in 
mice promotes cardiomyocyte and vascular cell formation and leads to an 
improvement in systolic function.99 If these findings can be reproduced, CSCs 
hold great promise for clinical applications. 
1.5.6 Candidates for myocardial regeneration or augmentation 
Stem and progenitor cell populations are currently available from a variety of 
sources including the embryonic cell mass, bone marrow, umbilical cord 
blood and placenta. Conceptually, autologous cells are the most appealing 
for clinical practice so that risks of infection or rejection are minimised; 
xenograft models have also been performed to determine the fate and 
viability of cross-species cell transfer. Each cell type has its own advantages, 
disadvantages and practicality issues in specific clinical settings; studies 
comparing the regenerative capacity of distinct cell populations are scarce 
(see Tables 1.5.1 and 1.5.2). Controversy remains as to the "ideal" stem cell 
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to use, with science in this area frequently and unfortunately clouded by self-
interest and financial imperatives. 
Embryonic Stem Cells 
Embryonic stem (ES) cells are totipotent stem cells derived from the inner 
cell mass of blastocysts and hold the greatest potential in terms of the 
diversity and number of cell types that could be produced. Under specific 
culture conditions, ES cells differentiate into multicellular embryoid bodies 
containing differentiated cells from all three germ layers including 
cardiomyocytes. The latter have been shown to display electrical coupling 
with host cardiomyocytes following transplantation into normal 
myocardium.101 However, unresolved ethical and legal issues, concerns 
about the tumorigenicity of the cells, and the need to use allogeneic cells for 
transplantation currently hamper their use in clinical studies. Eventually, 
nuclear transfer techniques and therapeutic cloning may provide a means for 
generating an unlimited supply of histocompatible ES cells for the treatment 
of cardiac disease. 
Skeletal Myoblasts 
Skeletal myoblasts, or satellite cells, are undifferentiated progenitor cells that 
normally lie in a quiescent state under the basal membrane of mature 
skeletal muscular fibres. Myoblasts can be isolated from skeletal muscle 
biopsies and expanded in vitro. Myoblasts differentiate into myotubes and 
retain skeletal muscle properties when transplanted into an infarct scar102.103. 
Although myotubes may not couple with resident cardiomyocytes 
electromechanically, myoblasts were the first clinically-relevant cells used in 
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transplantation models and have been shown to augment systolic and 
diastolic performance in animal models of myocardial infarction and clinical 
practice. 
Bone Marrow 
Many clinical investigators have chosen a pragmatic approach using 
unfractionated bone marrow cells (BMSCS)104.105 which contains a mixture of 
stem- and progenitor-cell populations, including haematopoietic stem cells 
(HSCs), endothelial progenitor cells (EPCs) and mesenchymal stem cells 
(MSCs). Ease of harvest and lack of extensive requirement for ex vivo 
manipulation are additional advantages of using unselected BMSCs. 
Endothelial Progenitor Cells 
EPCs were originally defined by expression of haematopoietic surface 
marker proteins CD133 and CD34 and the endothelial marker vascular 
endothelial growth factor receptor-2 (VEGFR-2) together with their ability to 
incorporate into sites of neovascularisation.106 lncreasing evidence suggests 
that culture-expanded EPCs also contain a CD14+/CD34- mononuclear cell 
population which mediates its angiogenic effects by releasing paracrine 
factors. 107 
Mesenchymal Stem Cells 
MSCs comprise a rare population of CD34- and CD133- cells in bone marrow 
stroma (10-fold less abundant than HSCs) and other mesenchymal tissues. 
MSC clones can be expanded in vitro and can readily differentiate into 
osteocytes, chondrocytes, and adipocytes. Differentiation to cardiomyocyte-
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like cells has been observed under specific culture conditions and after 
injection into healthy or infarcted myocardium in animals.108 When injected 
into infarct tissue, MSCs may enhance regional wall motion and prevent 
remodeling of the remote, non-infarcted myocardium. 
Umbilical cord blood-derived stem cells 
Umbilical cord blood (UCB) left behind in the umbilical cord and placenta 
after delivery provides a readily available, cheap and potentially autologous 
source of haematopoietic progenitor stem cells of various lineages 109 devoid 
of the ethical issues surrounding embryonic stem cells and provides a rich 
source of very primitive stem cells compared to bone marrow and peripheral 
blood.11o Additional advantages of CB include relatively naive immune status 
and well-preserved telomere lengths.111 
CD 133+ Cells 
The cell surface antigen CD133 is expressed on early HSCs and EPCs from 
bone marrow and cord blood and collaborate to promote vascularisation of 
ischaemic tissues. 112 CD133+ cells can integrate into sites of 
neovascularisation and differentiate into mature endothelial cells. Because 
CD133 expression is lost on myelomonocytic cells, this marker provides an 
effective means to distinguish ''true'' CD133+ EPCs from EPCs of 
myelomonocytic origin. Less than 1% of nucleated BMCs are CD133+ and at 
present, only limited numbers of CD133+ cells can be obtained for 
therapeutic purposes but improved results of ex vivo expansion are 
emerging.113 
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Tables 1.5.1 and 1.5.2 
The following tables summarise the results of key investigative work 
examining the efficacy of stem cell transplantation by cell type and 
xenogeneic model, respectively. 
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Table 1.5.1: Potential donor cells, advantages, 
limitations & practical issues 
Cell type Cell source 
Skeletal myoblasts Skeletal muscle biopsy 
Bone marrow 
Unfractionated bone marrow 
cells 
Endothelial progenitor cells Bone marrow, peripheral blood 
Mesenchymal stem cells Bone marrow/other 
mesenchymal tissues 
Fetal hematopoietic stem cells Cord blood 
Resident cardiac stem cells Cardiac muscle biopsy? 
Embryonic stem cells Allogeneic cell cells 
nd: not defined 
Ex vivo 
expansion? 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Capacity for transdifferentiation Paracrine Clinical data 
Cardiomyocytes Vessels effects Safety Efficacy 
No No Uncertain Uncertain Yes 
Probably no Probably yes Yes Yes Yes 
Uncertain Yes Yes Yes No 
Yes Uncertain Yes n.d. n.d. 
Probably yes Unknown Uncertain n.d. n.d. 
Yes Yes Uncertain n.d. n.d. 
Yes Yes Uncertain n.d. n.d. 
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Table 1.5.2: Cellular xenotransplantation for cardiac repair 
Cell type Animal 
model 
Somatic 
mAT_1114 Rat 
mAT-1 hFCSl15 Mlpig 
hFVS116 MI rat 
mHL-1117 Pig 
rFCs118 Mouse 
Adult stem cells 
mBSCsl19,120 MI rat 
Observation 
period 
Various 
1 month 
14-6S days 
4-S weeks 
2-8 weeks 
13 weeks 
Immunosuppression 
CY 5mglkg/d 
CY 1Smglkglbd 
CY 12.Smglkg/d 
CY 1Smglkg/d 
Results 
Survived, formed connection with host heart cells, 
angiogenesis 
Grafts formed close association with host myocytes, 
angiogenesis 
Survived in infarct, +ve staining for a-actin 
Engrafts in gap junctions and normal myocardium but 
not infarct 
CY Smg/kglbd+other Prolonged survival of xenografts 
No 
Grafts appeared in bone marrow and infarcted 
myocardium 
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Functional improvement, +ve staining for a-MHC and 
hMSCS121 Mlpig 6 weeks CY15mglkglbd cTn-1 
Graft +ve for B-MHC, a-actinin, cTn-l, desmin and 
hMSCSl22 Mouse 1-8 weeks Genetic manipulation phospholamban 
Grafts +ve for B-MHC, a-actinin, cTn-l, desmin and 
C2C12123 MI rat 1-8 weeks Genetic manipulation phospholamban 
Ischaemic 6 weeks-5 
hMYBsl24 pig months CY 5mg/kg/d Grafts +ve for desmin 
Embryonic Stem Cells 
Functional improvement, angiogenesis, grafts +ve for a-
mESCs 125,126 MI rat 6-32 weeks No MHC and cTn-1 
Functional improvement, angiogenesis, grafts +ve for 
mESCs127 MI rat 5 weeks No MLC2v, Cx-43 
Beating cells from 
mEBsl28 MI rat 30 days No Grafts +ve for sarcomeric myosin 
Colonisation of peri-infarct zone, 15% absolute 
Cardiac-committed Subset received CY difference In LVEF between control and cell-treated 
mESl29 MI sheep 1 month 500 mg/kg groups 
Fetal stem cells 
mHSCs CD133+ 116 MI rat 1 month Prevented scar thinning and LV systolic dilatation 
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1.5.7 Cell delivery 
Transvascular approaches 
Transvascular strategies are especially suited for the treatment of recently 
infarcted and reperfused myocardium when chemoattractants and cell adhesion 
molecules are highly expressed. Selective intracoronary application delivers a 
maximum concentration of cells homogeneously to the site of injury during first 
passage. Unselected BMCs, circulating blood-derived progenitors cells, and 
MSCs have all been administered to patients with AMI and ischaemic 
cardiomyopathy via the intracoronary route.130'132 In these studies, through the 
central lumen of an over-the-wire balloon catheter during transient balloon 
inflations to maximize contact time with the microcirculation of the territory 
supplied by the infarct-related artery. 
Intravenous delivery of EPCs or MSCs has been shown to improve cardiac 
function after AMI. However, homing of cells to non-cardiac organs133 could be 
considered to limit the clinical applicability of this approach. Indeed, in a recent 
study in post-AMI patients, significant myocardial homing of unselected BMCs 
was observed only after intracoronary stop-flow delivery but not after 
intravenous application. 134 
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Direct ventricular injection 
Direct injection is the preferred route for cell delivery for patients in whom 
occluded coronary arteries preclude transvascular cell delivery (for example 
patients with chronic myocardial ischaemia) or when cell homing signals are 
expressed at low levels in the heart (scar tissue). However, injection of cells into 
ischaemic or scarred myocardium could create islands of cells with limited blood 
supply leading to poor cell survival135 or the development of arrhythmogenic foci. 
Direct injection is especially suited for large cells, such as MSCs or myoblasts, 
which may otherwise cause microembolisation after intracoronary delivery. Cell 
delivery by direct injection may be technically challenging in patients with AMI, 
particularly if cells are to be injected into the border zone of the infarct. The 
safety of such an approach is questionable given the fragility of recently necrotic 
tissue. 
Alternatively, cells can be directly injected into endocardial aspect of the left 
ventricular wall using an injection needle catheter advanced across the aortic 
valve.136 Electromechanical mapping of the endocardial surface can then be 
used to identify viable, ischaemic, and scarred myocardium before cell 
injections. 
Transepicardial cell injection has been performed as an adjunct to coronary 
artery bypass grafting.137 Such an approach permits direct visualization of the 
myocardium and a targeted application of cells to scarred areas and/or the 
border zone of an infarct scar but its invasiveness limits its use as a stand-alone 
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therapy. The contribution of cell transplantation performed simultaneous to 
surgical revascularisation of ischaemic myocardium has been investigated in 
pre_clinicaI138,139 and clinical settings140,14\ but claims regarding tangible 
benefits using readily-available functional outcome markers have been harder to 
ascertain. More frequently, single-digit percentage improvements in ejection 
fraction have been reported142• The use of a needle catheter system placed via 
the coronary venous system has been described to deliver BMSCs through the 
coronary veins into normal porcine myocardium.143 The same approach has 
been used in a pilot trial in patients with ischaemic cardiomyopathy to deliver 
myoblasts to areas of nonviable myocardium.144 
1.5.8 Mobilization of stem and progenitor cells 
Rather than cell transplantation, recruitment and mobilisation of Circulating and 
extracardiac stem cells for the purposes of cardiac repair was conceived from 
attempts to increase EPC numbers in a model of hind limb ischaemia.107 Stem 
cell mobilization with stem cell factor (SCF) and/or granulocyte colony-
stimulating factor (G-CSF) has since been tested in animal models of AMI and in 
pilot studies in patients with AMI and chronic myocardial ischemia.145 So far 
results have been mixed: improvements in cardiac function after AMI in mice146 
have been countered by findings to the contrary in non-human primate147 and 
incidence of in-stent restenosis when combined with intracoronary stenting in 
humans. l48 Growth factors may also exert beneficial pleiotropic effects 
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independent of stem cells by enhancing macrophage infiltration and matrix 
metalloproteinase activation and suppression of cardiomyocyte apoptosis 
1.5.9 Transplantation Kinetics & Mechanisms of Action 
Given that a small fraction of cardiomyocytes may be able to re-enter the cell 
cycle and regenerate through recruitment of resident and circulating stem cells, 
experimental studies have been undertaken to further investigate the effect of 
stem and progenitor cell transfer into the heart. These studies have 
demonstrated significant, albeit often small, improvements in tissue perfusion 
and contractile performance of the ischaemically-injured heart. 
The mechanisms that might bring about such beneficial functional changes are 
the subject of ongoing debate. Following the dissemination of the early results of 
principally animal-based research, cell transplantation or "cellular 
cardiomyoplasty" has been explored clinically in a series small, mostly 
uncontrolled trials in patients unsuitable for existing therapeutic options such as 
revascularisation, transplantation or ventricular assist devices149• Preliminary 
efficacy data indicate that stem cells may enhance myocardial perfusion and/or 
contractile performance in patients with acute myocardial infarction, advanced 
coronary artery disease and chronic heart failure. 
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Some researchers favour engraftment by fusion150,151 or transdifferentiation152 
into cardiomyocyte or vascular cell lineages as likely explanations for these 
beneficial effects. Others have proposed that transient cell retention and release 
of paracrine mediators127,153 may be sufficient to effect functional improvement 
or bring about other advantageous changes by releasing angiogenic ligands to 
protect host cardiomyocytes from apoptotic cell death 154, inducing proliferation of 
endogenous cardiomyocytes, modulating local immunomodulation thus escaping 
detection and removal and may recruit resident cardiac stem cells. Today it 
remains controversial as to how mechanistically stem cell therapy might improve 
perfusion and contractile performance of the injured heart. Pre-clinical animal 
studies have provided some suggestions as to how this might occur but to date 
significantly-powered clinical trials have proved frustrating in terms of displaying 
tangible functional improvements using conventional functional outcome 
measures155• 
Early haematopoietic stem cell work 
In attempt to track the locational and phenotypic fate of cells following 
transplantation, Jackson et at lethally irradiated mice and then reconstituted 
their bone marrow with lacZ-labelied HSCs 156. Ten weeks later, cardiac injury 
was induced by occluding the left anterior descending (LAD) coronary artery for 
60 minutes. After 2-4 weeks, they found 0.02% of cardiomyocytes and 3.3% of 
endothelial cells in the peri-infarct region were b-gal+. This study lent support to 
the notion that bone-marrow-derived HSCs might contribute towards the 
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regeneration of myocardium, albeit in this study only slight functional 
improvements accompanied this and it was unclear to what extent cell fusion as 
opposed to true regeneration was responsible for the b-gal+ cell populations. 
In 2001, Orlic et al. took this further in an attempt to investigate the possibility 
that transplanted cells underwent differentiation rather than relying on innate 
bone-marrow-derived mechanisms for repair after myocardial injury92. They 
directly transplanted 1 xl 05 Lin"c-kit+ (HSC-enriched) bone marrow cells into the 
border-zone myocardium of mice several hours after LAD ligation. Surprisingly, 
they found new donor-cell-derived myocardium comprising 68% of the infarct 9 
days after transplantation. New myocytes, endothelial cells and smooth muscle 
cells, thought to be of donor origin, were detected. Moreover, ventricular function 
and haemodynamics were significantly improved in cell-treated animals 
compared with negative controls. This study drew enormous attention from both 
the scientific and clinical communities and set the stage for early human trials of 
bone marrow transplantation into the infarcted heart. 
As experimental models emerged supporting the hypotheSis that bone-marrow-
derived cells can transdifferentiate into cardiomyocytes, a clinical study by Deb 
et al.157 in human bone marrow transplantation provided further evidence. They 
found that, in the hearts of female reCipients of gender-mismatched bone 
marrow transplants, 0.23 ± 0.06% of the cardiomyocytes were Y chromosome 
positive. Thus it appeared that a small percentage of cardiomyocytes were 
derived from the donor bone marrow. 
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Cell Fusion 
The concept that stem cells possess plasticity to permit differentiation into 
different cell types depending on their local environment challenges a long-held 
dogma of developmental biology: that tissue-specific stem cells derive from the 
tissue that they repair. Transdifferentiation was met with a great deal of 
scepticism in stem cell biology circles, and several alternative theories were put 
forward to explain the unexpected scientific findings. 
A series of experiments by Wagers et ai, critically examined the hypothesis that 
HSCs can give rise to non-haematopoietic cells in ViV0158. Using a model in 
which bone marrow of lethally irradiated mice was reconstituted with a single 
GFP+ (green fluorescent protein-positive) HSC, they found little contribution of 
HSCs to non-haematopoietic tissue. In their analysis of cardiac tissue in these 
animals, not a single donor HSC-derived cardiomyocyte was detected. In a 
parallel series of experiments, they used a parabiotic mouse model to look for 
chimerism in non-haematopoietic tissues. GFP-transgeniclwild-type parabionts 
developed substantial haematopoietic chimerism over the study period, but 
chimerism was not noted in non-haematopoietic tissue. 
In 2002, further evidence emerged in support of the concept of fusion emerged 
as an alternative explanation for transdifferentiation events. Both Terada et al,159 
and Ying et al,l60 found that in co-culture experiments with bone marrow cells 
and embryonic stem cells or neural cells and embryonic stem cells respectively, 
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tetraploid hybrids could be detected that adopt embryonic stem cell 
characteristics. Using a Cre-Iox recombination system to detect cell fusion 
events in letha"y irradiated mice transplanted with labelled bone marrow cells, 
Alvarez-Dolado et ai, identified fusion of bone marrow cells with Purkinje cells, 
hepatocytes and cardiomyocytes161 • Camargo et ai, also used a single HSC 
transplant model to demonstrate that HSC-derived hepatocytes in fact occur as 
a result of cell fusion162• Interestingly, Oh et ai, found that Sca1+ cardiac 
progenitor cells delivered intravenously 6 h after cardiac ischaemialreperfusion 
differentiate into myocytes within the infarct border-zone, with approximately half 
of these cells representing fusion products between native myocytes and the 
infused stem cells97• In this model, they were unable to determine whether 
fusion preceded differentiation or vice versa. 
Re-examining the data on myocardial regeneration with HSC-enriched bone 
marrow and contemplating the human solid organ transplant experience, it is 
clear that only a minority of cells persist in the long-term following myocardial 
delivery. 
In response to Orlic et ai's study of 2001, which appeared to demonstrate that 
local implantation of HSC-enriched bone marrow into recently infarcted 
myocardium resulted in myocardial regeneration, several groups attempted to 
reproduce and extend these unexpected findings. The controversy surrounding 
Orlic's work was not really the identification of some of the 1.5x10sUn·c-kit+ 
bone marrow cells injected into the border-zone myocardium, but the purported 
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identification of extensive regeneration of myocardium at the 9-day post-
infarction study point. 
Balsam's lab performed a series of experiments to examine the ability of c-kit-
enriched bone marrow, Lin-c-kit+ bone marrow, and purified HSCs to regenerate 
myocardium after infarction94• After inducing myocardial ischaemia by LAD 
ligation in mice, donor bone marrow cells were implanted into the border-zone 
myocardium. Histological analysis using confocal microscopy was performed at 
10 and 30 days after infarction. Ten days after infarction, large number of cells 
were found in the areas of injection, but that by 30 days, the number of cells was 
much fewer. 
Thus 'engraftment' into the myocardium was not stable, but rather was transient. 
Moreover, the donor cells identified were small and round with a haematopoietic 
phenotype. By co-staining with a variety of markers, many of the donor cells in 
the c-kit-enriched donor group stained with the pan-haematopoietic marker 
CD45; in addition, nearly all of the donor cells in the Lin-c-kit+ and HSC donor 
groups were CD45+ and stained with the myeloid (neutrophil) marker Gr-1. 
Balsam concluded that. when bone marrow progenitors and HSCs are implanted 
into ischaemic myocardium, they do not transdifferentiate into cardiomyocytes; 
but instead adopt traditional haematopoietic fates, differentiating primarily into 
neutrophils. 
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One hypothesis to explain this functional benefit in the absence of myocardial 
regeneration is that cell treatment may result in increased angiogenesis through 
local release of growth factors. 
Nygren et al,95 published similar results for a series of experiments studying the 
fate of implanted bone marrow into ischaemic myocardium in mice. Using 
labelled whole bone marrow and Lin"c-kit+ cells as donor cells, they found that 
cells implanted into ischaemic myocardium after LAD ligation or cryoinjury 
maintained haematopoietic characteristics. Using both a 9-day and 28-day study 
point, they found transient engraftment of CD45+ cells at the sites of injection; 
that is, many more donor cells were noted at the 9-day study point when 
compared with at 28 days. Twenty-eight days after infarction, the majority of 
engrafted GFP+ cells within the heart were also CD45+. Rare GFP+ cells in the 
myocardium stained with cardiomyocyte markers (0.75% of all GFP+ cells 
analysed), but these were alllacZ+ as well. This provided conclusive evidence 
that bone-marrow-derived cardiomyocytes were products of cell fusion rather 
than transdifferentiation. 
Finally, Murry et ai, used a genetic reporter system to demonstrate that local 
implantation of HSC-enriched bone marrow into recently infarcted myocardium 
does not result in myocardial regeneration96. Mice were studied 1 to 4 weeks 
after infarction and implantation of Lin"c-kit+ cells into the peri-infarct zone; only 
small round donor-derived cells were noted, and none of these co-stained with 
cardiomyocyte markers. Murry's group also studied the ability of circulating 
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bone-marrow-derived cells to regenerate myocardium after infarction using 
GFP+ bone marrow chimaeric mice. The hearts were studied at 1 week to 2 
months after LAD ligation, and they found that only rare GFP-positive 
cardiomyocytes (1 to 3 cells/1 00,000 cardiomyocytes = 0.001 %). This study 
however was not designed to answer whether fusion or transdifferentiation 
resulted in this low level of cardiomyocyte repopulation. 
These three complementary studies raised many questions about the 
reproducibility and validity of the original bone marrow reports. Combined, they 
consistently demonstrate that local implantation of HSC-enriched bone marrow 
into ischaemic myocardium does not result in myocardial regeneration. Very low-
level myocardial regeneration from bone marrow may occur after infarction, with 
or without peripheral stem cell mobilization, and this is probably a consequence 
of cell fusion. These mechanistic studies are of particular importance and 
suggest that, although such cell therapy may be of functional benefit to patients, 
the mechanism for improvement is not myocardial regeneration. 
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1.5.10 Potential cardiovascular applications of stem cell therapy 
Non-ischaemlc cardiac disease 
Adult 
Considering that functional benefits of cell transplantation have also been 
observed in animals with dilated cardiomyopathy163,164 future trials may want to 
explore the role of cell therapy in patients with non-ischaemic heart failure. 
Anecdotal reports of recovery of cardiac function following cardiotoxic 
chemotherapy followed by bone marrow or cord blood transplantation would also 
lend credence to the possibility of stem cell repopulation. 
Congenital heart disease 
• Cell-based myocardial therapy 
Modulation of gene upregulation in response to increased 
workload 
Stimulation of resident cardiac stem cells 
• Tissue engineering of valves or conduits 
As mentioned earlier, it is becoming increasingly recognised that congenital 
heart disease may occur either as a result of deficiencies or alterations in 
developmental pathways leading to suboptimal phenotypes with regards 
cardiomyocyte number and extracellular composition. Often these patients must 
be palliated with a less then physiological arrangement, for example with a 
systemic morphological right ventricle. 
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It takes only a small mind shift from an emphasis on regeneration in the adult to 
augmentation of the cardiovascular situation in the pediatric field. Opportunities 
for antenatal intervention are limited since by the time a fetal echocardiogram 
has been performed with a sufficient degree of certainty the practicalities of any 
intervention other than practical, flow-directed ones have missed the boat and 
almost certainly, "rescue" of the secondary heart field would be speculative. 
With this in mind, the favourable modulation of natural history may be possible 
by supplementation with autologous or allogeneic stem cells with the intention of 
repopulating the heart with new cardiomyocytes or augmenting cardiac growth 
and function in the face of increased functional demands. 
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2.0 Differences in extra-cellular matrix and myocyte homeostasis 
between the neonatal right ventricle in 
Hypoplastic Left Heart Syndrome and Truncus arteriosus 
2.1 Abstract 
Objectives 
The right ventricle in hypoplastic left heart syndrome (HLHS) works at systemic 
pressure and large volume loading before and after 1 st stage palliation. There is 
a paucity of information regarding the intrinsic characteristics of the right 
ventricle in HLHS. We studied extra-cellular matrix composition, myocyte 
homeostasis and gene expression in right ventricular biopsies obtained from 
patients with HLHS undergoing neonatal 1 st stage palliation and from patients 
undergoing neonatal truncus arteriosus repair. 
Methods 
Tissue was evaluated using histological and real time peR techniques using the 
truncus group used as a comparative group. Mean difference in outcomes 
between the HLHS and truncus groups were estimated using linear regression 
models in unadjusted and age-adjusted analyses. 
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Results 
Markers of cell proliferation, apoptosis and fibronectin were significantly higher 
in the right ventricular myocardium of patients with hypoplastic left heart 
syndrome compared to truncus arteriosus. Type I collagen content and NKX2.S 
expression were significantly lower in HLHS than the truncus group. 
Conclusion 
The neonatal right ventricle in HLHS demonstrates a number of intrinsic 
differences compared to the right ventricle in truncus arteriosus including relative 
immaturity of the extracellular matrix, inappropriately low transcription factor 
expression and increased myocyte apoptosis. 
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2.2 Introduction 
The right ventricle (RV) in hypoplastic left heart syndrome (HLHS) works at 
systemic pressure and increased volume loading before and after stage 1 
palliation. There is growing evidence that the right ventricle of palliated HLHS 
patients has reduced function compared to other univentricular hearts with 
similar parallel circulations 165-167. Despite innovations in surgical techniques and 
intensive care3,4.168, HLHS patients experience a more precarious course and 
persistent risk of early death than other palliated complex cardiac anomalies. 
Little is known regarding the intrinsic structure of the right ventricular 
myocardium in HLHS. Analysis of archived HLHS specimens has identified 
reduced cardiac extracellular matrix collagen content that might contribute to 
myocyte slippage and suboptimal ventricular function169• Changes in myocyte 
homeostasis characterised by increased apoptosis and progressive net myocyte 
loss are known to contribute to ventricular dysfl:Jnction in both ischemic and non-
ischaemic heart disease17o,171. Differing myocardial composition and 
homeostasis in HLHS might affect the right ventricle's ability to adapt to the 
obligatory volume loading, increased wall stress and changes in coronary 
perfusion that accompany stage I palliation. 
The modification of the originally described Norwood procedure to include a 
restrictive RV to PA conduit has also allowed access to right ventricular 
biopsies. The right ventricle in neonates with truncus arteriosus works under 
similar workloads with parallel circulations and large volume loading. Neonatal 
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repair of truncus arteriosus is the only procedure that provides access to RV 
samples both of similar age and where the loading conditions of the RV are 
similar to the un-palliated HLHS. The purpose of this cross-sectional 
comparative study was to ascertain whether the intrinsic properties of the right 
ventricular myocardium differ between patients with HLHS and truncus 
arteriosus (T A) in order to improve understanding of the response of the right 
ventricle to surgery and increased load. 
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2.3 Methods 
Patient data 
Right ventricular myocardial biopsies were obtained from infants undergoing 
stage I Norwood procedure for typical HLHS (n=14) or neonatal repair of truncus 
arteriosus (n=7). Diagnosis of hypoplastic left heart syndrome was made by two-
dimensional echocardiography and required underdevelopment of the left heart 
with significant hypoplasia of the left ventricle including atresia, stenosis or 
hypoplasia of the aortic or mitral valves, hypoplasia of the ascending aorta and 
aortic arch with duct-dependent systemic circulation and retrograde flow in the 
aortic arch. Patients with unbalanced atrioventricular septal defect or 
univentricular hearts with subaortic stenosis requiring Damus-Kaye-Stansel 
connection and shunt palliation in the neonatal period were excluded. Six 
patients with truncus arteriosus were of type 1 variant and one type 4. Median 
age at operation for HLHS and TA patients was 3.0 days (range, 2 to 8) and 
14.0 days (range, 5 to 44), respectively. All patients were born after 38 weeks of 
gestation. One patient in the HLHS group had gut malrotation which required 
later correction. Two truncus arteriosus patients had 22q deletion and another 
had Di George syndrome. The study was approved by the Royal Children's 
Hospital Ethics in Human Research Committee and parents gave informed 
consent. 
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Table 2.1: Patient demographics 
HLHS Truncus pvalue 
(11=14) (11=7) 
Male gender 10 3 NA 
(n) 
Age at operation 3.0 (2 to 8) 14.0 (5 to 44) <0.001 
(days) 
Weight 3.3 (0.55) 2.75 (0.43) 0.09 
(kg) 
BSA 
(m2) 0.20 (0.02) 0.18 (0.02) 0.28 
eSA: Body surface area 
Age, weight and eSA data presented as mean (SO) or median (range) 
p-values based on I-test for weight and eSA on Mann-Whitney test for age at 
operation. 
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Operative details 
All stage I reconstruction procedures for HLHS were performed using right 
ventricle to pulmonary artery conduits as the source of pulmonary blood flow. 
Norwood operations were conducted using continuous cardiopulmonary bypass 
at a systemic temperature of 2SoC. A 3.Smm diameter polytetrafluoroethylene 
graft was anastomosed end-to-side to the innominate artery and a cannula 
inserted at this level initially to maintain systemic perfusion. During arch repair 
the innominate artery was clamped and flow maintained through this cannula to 
provide antegrade regional perfusion at 30% of minimum predicted flow guided 
by inline and right upper limb arterial pressures. Coronary and lower body 
systemic perfusion during this phase was maintained via separate 2mm and 
4mm diameter olive-tipped cannulae snared within the ascending and 
descending aorta, respectively to permit arch reconstruction with a beating 
heart. Repair of truncus arteriosus was carried out in the first month of life in 
keeping with the centre's routine practice, using aortobicaval cardiopulmonary 
bypass at 32°C. Intermittent antegrade cold blood cardioplegia was used in both 
groups; after giving half of the induction dose of cardioplegia at 32°C, the 
remainder together with further maintenance doses at 20 minute intervals were 
given at 24°C. Thus the myocardium in both groups was unloaded and arrested 
at equivalent temperatures. For a diagrammatic summary of the series of 
operations performed for HLH5 and truncus arteriosus, please see Figures 52.1 
and 52.2, respectively in the supplementary data section. 
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Transmural cylindrical cores of tissue were obtained from equivalent regions of 
the right ventricular free wall selected for ventriculotomy, below the pulmonary 
valve and adjacent to the left anterior descending artery. Samples were 
assigned a code to blind their origin and snap frozen in liquid nitrogen to 
optimally preserve immunogenicity until analysis. 
Immunohistochemistry 
Sllm sections from HLHS and TA tissue were mounted side-by-side on silane 
slides and fixed with 4% paraformaldehyde. Sections underwent treatment for 
antigen retrieval and were then incubated in a blocking solution to reduce non-
specific binding. For each investigational target, a further 10 sections were 
prepared from the mesocardiallayer of each sample. In all cases sections were 
double-stained with antibodies of different species origin using the second stain 
as an internal control to verify adequate preparation and staining. If the 
accompanying target did not stain correctly the run was repeated. 
Primary antibodies were: ACAM/N-cadherin, a-sarcomeric actin, connexin-43 
(all Sigma-Aldrich, Castle Hill, Australia), caspase-3 active (R&D Systems, 
Minneapolis, USA), collagen types I and III (Southern Biotech, Birmingham, 
USA), desmin, fibronectin (both DakoCytomation, Denmark), heavy chain 
cardiac myosin (Abcam, Cambridge, UK), NKX2.S (Santa Cruz Biotech, Santa 
Cruz, USA), phosphorlyated histone H3 (Upstate, Charlottesville, USA) and 
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human troponin T (Chemicon, Temecula, USA). Secondary antibodies 
conjugated to the fluorophores Alexa Fluor 488 or 594 (Becton Dickinson) were 
used. Co-localisation of cardiac heavy chain myosin or troponin T with other 
markers of interest was used to verify their myocytic disposition. 
DNA-strand breaks in myocytes 
Myocyte apoptosis was also investigated by labelling nuclear DNA strand breaks 
with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling 
(TUNEL) and counterstaining nuclei with 4',6-diamidino-2-phenylindole using a 
proprietary kit (Roche Diagnostics, Castle Hill, Australia). Tissue was labelled for 
TUNEL and myosin or desmin to delineate cell type. Nuclei were counterstained 
with 4',6-diamidino-2-phenylindole (Vector Laboratories, Burlington, USA). The 
total number of cardiomyocyte nuclei in ten random high-power fields was 
identified, and the percentage of these containing TUNEL-Iabelled DNA breaks 
calculated. 
Image capture and analysis 
Slides were evaluated using fluorescent inverted (Olympus IX70, Olympus 
Corp., Tokyo, Japan) and laser scanning confocal microscopy (Leica TCS SP2 
SE, Leica Microsystems GmbH, Wetzlar, Germany) with proprietary software 
(Spot version 3.4.2, Diagnostic Instruments Inc, Sterling Heights, USA) without 
gamma correction. Background levels of autofluorescence on unstained sections 
and those incubated with secondary antibodies only were used as controls. 
Images of the microscope field were acquired using a monochromatic camera 
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and proprietary software (Spot version 3.4.2, Diagnostic Instruments Inc, 
Sterling Heights, USA) without gamma correction. Once established for each 
target of investigation, microscope settings were retained throughout the series. 
Ten random fields were recorded from each section for later analysis. The 
microscope operator was blinded to the origin of the sections. Monochromatic 
image content was evaluated using an automated counting program and pre-
specified morphometric criteria (ImagePro Plus, Media Cybernetics, Silverspring, 
USA). Mean intensity per microscope field was also recorded as in some 
circumstances this measurement better represented tissue staining. To avoid 
overestimation, areas immediately adjacent to blood vessels were excluded from 
assessment. False colours were later assigned to aid recognition upon merging 
images of the multiply-stained sections. 
Real-time Polymerase Chain Reaction 
Total RNA was extracted from samples of right ventricular myocardium from 
both patient groups using RNeasy (Qiagen) and reverse transcribed into cDNA. 
One J.lg of RNA sample was reverse transcribed using MML V Reverse 
transcriptase (Promega Corporation) and cDNA stored at -20°C. Intron-
spanning primer sequences were selected for B2 microglobulin and NKX2.5; 
primer sequences are available in the Data Supplement. Real-time polymerase 
chain reaction (PCR) assays were carried out in triplicate using SYBR Green 
Master Mix (Sigma Aldrich) and a real-time PCR thermal cyclerlfluorescence 
detection system (Rotor-Gene 3000, Rotor Gene Pty, Australia). 25JJL PCR 
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reactions included 12.SJ.lL of SYBR Green 2x Master Mix (Sigma Aldrich) and 
1.0J.lL of cDNA. Melting curve analysis was performed after the final PCR cycle 
to check for the presence of non-specific PCR products and primer dimers. We 
analysed relative differences in 2-AACT values after normalising data using B2 
microglobulin as a housekeeping gene. 
2.4 Data analysis 
Mean scores of intensity and count derived from histological data were 
calculated for each patient. These mean scores were used as the observations 
in our analyses to circumvent issues with analysing correlated data172• The 
distribution of the outcome variables was examined using normal probability 
plots. Means and standard deviations are presented for the outcomes separately 
for each group. Linear regression was used to compare the mean outcome 
between the HLHS and truncus groups in unadjusted analyses and analyses 
that were adjusted for age as a linear effect. Partial residual plots did not 
suggest that the effect of age was non-linear for any of the 14 outcomes. There 
was little overlap in age between the comparison groups and the 
appropriateness of using linear regression to adjust for age relies on the 
relationship between outcome and age being the same in each comparison 
group. In order to assess this, scatterplots were drawn. Because some of the 
outcomes were not normally distributed and the sample size was small, bias 
corrected accelerated (BCA) bootstrap confidence intervals 173 were constructed 
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to validate the assumptions underlying the confidence intervals from the linear 
regressions. The non-parametric bootstrap algorithm was used to construct 
2000 bootstrap datasets for each analysis. Where the bootstrap intervals were 
similar to those from the main analyses the latter results are presented. Where 
they were considered to be different the bootstrap intervals are presented. All 
data were analysed using Stata 9.0 (StataCorp, College Station, Texas, USA). 
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2.5 Results 
Table 2.2 shows the results of image analysis for each of the variables, 
displaying mean count, mean intensity or percentage TUNEL positive nuclei per 
random microscope field. 
Table 2.2: Results of immunofluorescent and histochemical analysis 
Marker Unadjusted Adjusted 
HLHS Truncus Mean Mean 95% confidence 
Mean (SO) Mean (SO) difference difference intervals 
Caspase-3 C 65.8 (24.4) 34.8 (19.3) 30.9 19.0 -11.9 to 49.9 
36.3 (6.8) 23.4 (3.1) 12.9 11.8 3.59 to 20.0 
TUNEL 0/0 1.43 (0.36) 0.67 (0.19) 0.76 0.70 0.26 to 1.14 
PH3 C 103.3 (33.6) 77.B (26.5) 25.4 46.6 12.B to 95.4 
39.3 (13.1) 30.7 (7.3) B.7 6.2 -10.0 to 22.3 
Collagen I C 165.1 (21.2) 218.7 (15.5) -53.7 -45.5 -76.8 to -27.8 
40.7 (3.0) 40.8 (4.4) -0.1 -2.3 -7.0 to 2.4 
Collagen III C 41.3 (15.0) 70.8 (32.6) -29.4 -19.3 -60.0 to 49.2 
31.6 (3.4) 34.4 (4.9) -2.8 0.7 -4.3 to 5.6 
Fibronectin C 417.8 (5B.6) 303.5 (120.5) 114.3 159.5 -12.0 to 314.3 
50.8 (3.2) 35.3 (6.6) 15.56 17.2 10.9 to 23.5 
NKX2.5 C 118.2 (14.9) 204.7 (13.8) -B6.5 -62.5 -60.1 to 186.2 
26.B (4.3) 35.2 (4.7) -9.4 -7.9 -14.1to-l.7 
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p 
0.007 
0.004 
0.03 
<0.001 
0.02 
Microscope field's mean intensity 
C Automated count for discrete/nuclear activity 
PH3 Phosphohistone H3 
* Where bootstrap method used, p value not shown 
95% confidence intervals not containing zero imply p<O.05 
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Cell replication and apoptosis 
Cell replication, as indicated by the presence of phosphohistone-H3, was 
significantly higher in the HLHS group compared to TA (mean count 103.3 vs. 
77.8; age-adjusted p::0.03) as depicted in Figures 2.1a, 2.1b, 2.1c. To 
investigate myocyte apoptosis in HLHS, separate heart sections were stained 
for caspase-3 active or TUNEL. Apoptosis was assessed by staining for 
caspase-3 active, a key apoptotic mediator and member of a multigene family of 
cysteine proteases that cleave key cellular proteins, leading to the apoptotic 
demise of cells. Mean intensity of caspase-3 active staining in the HLHS group 
was significantly higher compared to TA (mean intensity 36.3 vs. 23.4; age-
adjusted p:O.007, Figure 2.2). The frequency of myocyte apoptosis in the 
truncus arteriosus group as demonstrated by TUNEL staining was 0.67% of 
cardiac nuclei. In contrast, the frequency of myocyte apoptosis in HLHS tissue 
was 1.43%, twice as high as in TA (age-adjusted p::0.004) (Figures 2.3a, 2.3b). 
These data demonstrate that myocyte apoptosis is higher in HLHS than in TA. 
Extracellular matrix 
Type I collagen content was significantly lower in HLHS compared to TA, (mean 
count 165.1 vs. 218.7; SCA 95% confidence intervals -76.82 to -27.77, figures 
2.1 a, 2.1 b, 2.4). This was accompanied by increased fibronectin content in 
HLHS (mean intensity 50.8 vs. 35.3; age-adjusted pc:O.001) as shown in figure 
2.5. There were no significant differences in type III collagen nor laminin. 
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Cardiac transcription factors 
Semi-quantitative indirect immunofluorescent staining for the cellular expression 
of NKX2.5 was significantly lower in HLHS compared to TA (mean intensity 26.8 
vs. 35.2; age-adjusted p::0.02) as shown in Figure 2.6a. Real time peR showed 
that NKX2.5 expression was significantly lower in HLHS compared to TA (mean 
relative concentration 0.62 vs. 0.98; age-adjusted p::0.04). Figures 2.6b and 
2.6c. 
Cardiac proteins 
There were no statistically significant differences in the relative content of 
cardiac (heavy-chain myosin, troponin T), intermediate (desmin), 
transmembrane proteins (ACAM) nor connexin-43. 
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2.6 Discussion 
Outcomes for staged surgical reconstruction for HLHS have improved174,175, 
however patients continue to experience impaired systemic cardiac output, RV 
dysfunction and tricuspid regurgitation, leading to increased risks of morbidity 
and mortality. Whilst there is a paucity of knowledge concerning the myocardial 
composition of the right ventricle in HLHS, imaging studies have demonstrated 
impaired right ventricular function in patients with HLHS compared to other 
single-ventricle physiologies166,167,176, In this study, we have shown the 
composition of the right ventricular myocardium in HLHS to differ significantly 
compared to truncus arteriosus despite similar loading conditions even when 
mitigating for age. 
Cardiac development and transcription factors 
During fetal development, myocardial growth is co-ordinated by transcription 
factors including NKX2.S which orchestrate developmental gene expression, 
cardiac-lineage determination and the formation of the multi-chambered heart1n. 
Myocardial NKX2.S expression normally undergoes a temporal decline from 
embryogenesis onwards, remaining at low levels post-natally where it assists in 
maintaining cardiac phenotype and facilitates responses to changing functional 
demands such as pressure overload178,179. 
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Knock-out murine models have highlighted the importance of NKX2.5 in normal 
structural development180, however similar mutations are relatively uncommon in 
clinically-pertinent structural phenotypes7 which are likely to originate from 
interactions between multiple genetic and environmental influences. In this 
study, we found NKX2.5 expression to be significantly lower in the right 
ventricular myocardium of HLHS patients compared to those with TA, even 
when adjusting for age and despite similar right ventricular loading conditions. 
These differences are contrary to predicted chronological changes where higher 
levels of NKX2.5 would be expected in the younger HLHS group. It is therefore 
plausible that NKX2.S expression either makes a positive contribution to a 
dynamic ventricular phenotype including adaptation to loading conditions, or that 
it is widely indicative of a chain of appropriate adaptive responses 181. 
C a r d r o m y o c ~ e h o m e o s ~ s ~ ~
The transition from late intra-uterine to neonatal life is normally accompanied by 
an increase in myocardial mass achieved prinCipally by cellular hypertrophy with 
simultaneous cardiomyocyte cycling and renewal to aid adaptation to changes in 
hemodynamic workload182. Increased cell replication and apoptosis in the HLHS 
group, as manifest by increased expression of phosphohistone-H3 and caspase-
3 active together with TUNEL staining may reflect attempts at adaptation in 
response to increased loading conditions simultaneous to ongoing myocyte loss. 
These findings, when considered with the reduced expression of NKX2.S 
observed in the HLHS group suggests a different myocardial phenotype 
65 
compared to the truncus arteriosus group. As alluded to above, reduced levels 
of NKX2.S may diminish recruitment and proliferation of new, and maintenance 
of existing cardiomyocytes or inhibit rescue from apoptosis, a phenomenon 
previously observed in the development of the cardiac conduction system of 
NKX2.S knock-out mice46• 
Extracellular matrix 
The extracellular matrix provides structural support to the myocardial 
interstitium, maintaining myocyte alignment, minimising slippage and permitting 
interdigitation throughout the cardiac cycle. The heart's principal extracellular 
matrix components are collagen types I and III and fibronectin. Typically 
extracellular matrix in the late embryonic period exhibits a shift in the 
fibronectin:collagen ratio in favour of collagen which serves to increase tissue 
robustness 183, a phenomenon which also usually occurs in right ventricular 
hypertrophy induced by pressure overload184• In this work, type I collagen 
content was found to be significantly lower in the mesocardium of HLHS 
compared to T A and accompanied by increased expression of fibronectin in 
HLHS. The reduced content of type I collagen and increased fibronectin in the 
HLHS group may represent an inability to make such a switch or relative 
immaturity and may lead to greater ventricular compliance. 
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Implications 
The findings of this novel work support the notion that the neonatal systemic 
right ventricle in HLHS may be less able to adapt to increased loading conditions 
than the one in truncus arteriosus. In patients undergoing surgical reconstruction 
for HLHS, suboptimal right ventricular geometric and myocardial characteristics 
are compounded by a 40% increase in the hydraulic cost of work associated 
with the loss of a biventricular heart185• This may contribute to the more 
precarious course of these infants and supports the rationale for 
pharmacological or mechanical off-loading following stage I procedures. 
Limitations 
In view of the limited quantities of tissue available, we elected to use 
immunofluorescent histological techniques and real-time peR to investigate 
several targets of interest. With immunofluorescence, quantification of the 
various markers does not necessarily infer activity or efficacy of the gene 
products themselves where applicable nor their possible post-translational 
modification. We did not attempt to identify and correlate pre-operative risk 
factors nor outcomes to histological findings between groups. 
An important limitation in this study is the differing maturity of the right 
ventricular myocardium in the two patient groups. We chose neonatal truncus 
arteriosus patients as a group for comparison because the right ventricle in 
neonatal truncus patients also works under increased pressure and volume 
loading conditions that would be comparable to the right ventricle in hypoplastic 
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left heart syndrome. In a study of this type, it is ideal to have age-matched 
subjects. However, in our institution we do not perform any other surgery in the 
first week of life that involves the routine removal of right ventricular 
myocardium. Similarly it is not possible to obtain myocardium from fresh, 
structurally-normal neonatal hearts in Australia for ethical reasons and TAwas 
used in preference to other neonates with right to left shunts who lack significant 
volume loading. 
The precise intra-operative timing of the biopsies between the two groups 
differed slightly but significant structural changes are unlikely within this 
timeframe. All study patients were born at or after 38 weeks gestation so 
prematurity should not be a confounder. There were fewer truncus samples than 
HLHS. Differences in age between the two groups were unavoidable. 
Scatterplots of outcome against age did not indicate a similar relationship for the 
HLHS and truncus groups for caspase-3 intensity, NKX2.S intensity and type I 
collagen count and the effectiveness of age adjustment may be questioned here. 
The scatterplots for PH3 count, TUNEL and fibronectin intensity, however, did 
suggest the use of linear regression for age adjustment was appropriate and, 
overall, the pattern of results indicates morphological trends not explained by 
expected age-related changes alone. 
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Conclusion 
This study has demonstrated a number of intrinsic differences between right 
ventricular myocardium in patients with HLHS and truncus arteriosus, Differing 
myocardial composition and myocyte homeostasis might affect the ability of the 
right ventricle to adapt to the obligatory volume loading, increased wall stress 
and changes in coronary perfusion that accompany stage I operations and 
resulting parallel circulation. Improved understanding of the composition of the 
right ventricle in hypoplastic left heart syndrome may help inform future 
treatment strategies in this group of patients. 
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2.7 Figures 
Figure 2.1 Representative photomicrographs of immunofluorescent staining 
for Phosphohistone H3 (red) and Type I Collagen (green); x400 
Figure 2.1a Hypoplastic left heart syndrome (HLHS) 
Figure 2.1 b Truncus arteriosus 
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Figure 2.1 c Scatterplot of phosphohistone H3 count against age in days. 
HLHS outcomes are displayed as round dots and solid lines and 
T A with triangles and dashed lines, respectively 
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Figure 2.2 Scatterplot of activated caspase-3 staining intensity in the right 
ventricle of patients with hypoplastic left heart syndrome and 
truncus arteriosus against age in days. HLHS outcomes are 
displayed as round dots and solid lines and T A with triangles and 
dashed lines, respectively . 
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Figure 2.38 Percentage of TUNEL-positive cardiomyocyte nuclei in right 
ventricular myocardium in patients with hypoplastic left heart 
syndrome (H) and truncus arteriosus (T). 
TUNEL positivity was significantly greater in HLHS than in TA. 
Results are shown as mean ± SEM. 
* significant difference where p<O.05 
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Figure 2.3b Scatterplot of percentage TUNEL-positive cardiomyocyte nuclei in 
the right ventricle of patients with hypoplastic left heart syndrome 
and truncus arteriosus against age in days. HLHS outcomes are 
displayed as round dots and solid lines and T A with triangles and 
dashed lines, respectively . 
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Figure 2.4 Scatterplot of type 1 collagen count in the right ventricle of patients 
with hypoplastic left heart syndrome and truncus arteriosus against 
age in days. 
HLHS outcomes are displayed as round dots and solid lines and 
TA with triangles and dashed lines, respectively. 
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Figure 2.5 Scatterplot of fibronectin staining intensity in the right ventricle of 
patients with hypoplastic left heart syndrome and truncus 
arteriosus against age in days. 
HLHS outcomes are displayed as round dots and solid lines and 
T A with triangles and dashed lines, respectively. 
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Figure 2.6 Results of NKX2.S studies 
Figure 2.68 Scatterplot of NKX2.S immunofluorescent staining intensity in the 
right ventricle of patients with hypoplastic left heart syndrome and 
truncus arteriosus against age in days. HLHS outcomes are 
displayed as round dots and solid lines and TA with triangles and 
dashed lines, respectively. 
A 
A 
A 
---
------_. 
-----
------
f ~ ~ -----E- -----A 
• A 
• III 
•• Si • z 
i \ ~ ~
• I 
• ~ ~
0 10 20 30 40 50 
Age (days) 
77 
Figure 2.6b NKX2.5 expression as determined by real-time peR 
(Mean ± SEM) by group, unadjusted for age. * p=O.001 
* 
H T 
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Figure 2.6c NKX2.S expression determined by real-time peR against age, with 
linear regression lines (Truncus group boxes with dashed line, 
HLHS circles and solid line). Regression analysis shows significant 
inter-group differences for both unadjusted (p=O.001, Fig 2.6b) and 
age-adjusted analyses (p=O.04, Fig 2.6c) 
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3.0 Umbilical cord blood stem cells - a potential source of stem cells 
for ventricular augmentation in congenital heart disease? 
3.1 Introduction 
As outlined in the first chapter, post-natal and adult cardiac myocytes have been 
shown to adapt and regenerate in response to changes in loading conditions98 
or ischaemic damage93,186. In addition the concept of the tissue- or organ-
specific stem cell has gained acceptance99,100,187. 
In the paediatric age range, coronary artery disease is rarely an issue and 
instead owing to congenital structural heart disease, the heart may be 
functionally disadvantaged because of obligatory supranormal haemodynamic 
loads due to shunting, the lack of two functionally ventricles. or acquired 
cardiomyopathies which directly impair myocardial function. 
One avenue to approach the struggling heart could be to stimulate it by directly 
providing growth factors or indirectly via a paracrine effect, using a population of 
cells that could produce the same, irrespective of the still-disputed issues of 
whether such transplanted cells might integrate into the recipient via cell fusion 
transdifferentiation. A pharmacological precedent for such a process already 
exists. Clenbuterol, an anabolic steroid and 62 agonist, has been used to 
encourage an improvement in cardiac function firstly in animal models1B8-190 and 
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then in human trials of heart failure combined with mechanical circulatory 
support191 ,192 . 
Exogeneous stem cell transplantation into the heart might augment the 
adaptation of existing myocytes, increase cell cycling and recruit senescent cells 
into the functioning myocyte pool to promote a net increase in the functional 
myocyte mass and bring about an overall improvement in systolic and diastolic 
cardiac function . 
Figure 3.1 Myocardial homeostasis 
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3.1.2 Why use cord blood stem cells? 
Umbilical cord blood stem cells (CSSC) are readily available, free of ethical 
controversy and have an established track record as an alternative to bone 
marrow transplantation for stem cell reconstitution in the treatment of 
haematological disorders including genetic disease and haematological 
malignancies.193 This has provided the foundations for many key stem cell 
biology research laboratory protocols and is remarkable for a resource once 
considered a redundant by-product of birth before its therapeutic potential was 
realised in the late 1980s.194 
Cord blood contains an abundant, heterogeneous mixture of haematopoietic, 
mesenchymal and endothelial progenitor cells that are self-renewing, clonal 
precursors of both haematopoietic and non-haematopoietic tissues195. A typical 
cord blood unit, typically between 100 and 120 ml in volume, provides a 
workable and scaleable quantity of high quality stem cells. Human CSSC have 
many advantages that might be relevant to cardiac' cell therapy: they are rich in 
a variety of stem and progenitor cells with improved numbers and proliferative 
characteristics relative to other cell sources.110 
Cord blood stem cells, including haematopoietic and mesenchymal populations, 
can be expanded in vitro,109 have the potential for enhanced self-renewal and 
angiogenic and myogenic ditferentiation196,197 and can be stored for future use. 
Several studies have suggested that bone marrow- and cord blood-derived cells 
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can contribute to multiple non-haematopoietic tissues, including neurons198, 
hepatocytes, skeletal muscle and cardiomyocytes195,199,200. If and quite how this 
occurs, either through fusion events or transdifferentiation, remains contentious. 
It appears that there is reduced risk of rejection by the recipient's immune 
system with CB-derived stem cells.201 Homing experiments have demonstrated 
that CBSCs can traffic through the intact human system to where they are 
required202 and lineage-negative cell fractions enriched for the expression of 
CD34 are able to engraft in ovine and murine models over the longer term203. 
Haematopoietic stem cells 
Haematopoietic stem cells, which comprise a significant proportion of stem cells 
within cord blood" are probably the best characterised tissue-specific stem cell. 
The traditional marker for immature HSC has been the CD34 antigen, a 
molecule with an important role in key migratory events including homing and 
adhesion. A long history of translational work in laboratory and clinical arenas 
has established some of the fundamental tenets of stem cell biology and at the 
same time advanced the treatment of haematological malignancies204-206. For 
example, differentiation, multi potentiality, and self-renewal were first 
demonstrated by Till and McCulloch who discovered that a subset of bone 
marrow cells could form macroscopic colonies upon transplantation into the 
spleens of lethally irradiated recipient animals207. The demand for greater 
mechanistic insights drove the development of technologies such as in vitro and 
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in vivo assays, fluorescence-activated cell sorting and monoclonal antibody 
technology, which are today taken for granted. HSCs were the first tissue-
specific stem cells to be prospectively isolated208 and today, heterologous bone 
marrow and cord blood remain the only stem cells in routine clinical use for the 
treatment of leukemias and autoimmune disorders209. The potential of utilising 
such stem cells, traditionally the preserve of haematologists, has stimulated 
several scientists, including those working in the cardiovascular field, to consider 
novel therapeutic applications for umbilical cord blood and bone marrow. 
Bone marrow stem cells comprise a heterogeneous mixture of mesenchymal 
and haematopoietic stem cells that are relatively easy to collect, purify and 
store. For these reasons, bone marrow was selected for early pre-clinicaI92,94 
and clinical210 work relating to ischaemic heart disease. Umbilical cord blood is 
arguably more attractive as a practical source of stem cells as it circumvents the 
ethic issues surrounding other cell types which is remarkable for a resource 
once considered a redundant by-product of birth before its therapeutic potential 
was realised in the late 1980s.194This. Cord blood contains HSC and MSC in 
relative abundance (see figures 3.2a and b) and a typical cord blood unit 
contains a workable and scaleable quantity of stem cells even at full term. 
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Figure 3.1.28 Relative abundance of primitive human haematopoietic cells 
in cord blood (CB), bone marrow (BM) and mobilised 
peripheral circulating blood (PB), where the engrafting 
human cell was defined as a SCID-repopulating cell 
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It is likely however that haematopoietic cells do what they are programmed to do 
and that expectations defying biological rules were not justified. Indeed several 
reports using HSCs in animal models of myocardial infarction demonstrated that 
transplanted cells maintain a haematopoietic phenotype212• Even in the absence 
of transdifferentiation improvements in cardiac function undeniably occur 
following ischaemic insults. C8-derived stem cells might improve resident stem 
cell function and therefore pump function in degenerative heart disease. 
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Other non-ischaemic forms of cardiac disease in different age groups have also 
benefited from cellular transplantation or cell-delivered gene therapy, Examples 
include the response to artificially-created dilated cardiomyopathies213 or 
supraphysiological workload214 ; we have developed the latter principle in a 
novel, neonatal large animal model of right ventricular training: 
The beneficial functional effects witnessed in these studies therefore probably 
results from the production of paracrine factors although the precise 
mechanisms remain poorly understood215 , 
Figure 3.1.4 Proposed mechanisms for mediating improved cardiac function by 
exogeneous progenitor cells216 
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It is on this constantly changing background that we had to choose how best to 
characterise our cells. Taking a lead from existing cell therapy protocols used 
clinically for the treatment of haemato-oncological disease, we settled on CD34, 
CD33, CD38 and CD45. Criticism could be forthcoming for not including CD133 
in this list, as CD133+ populations are known to have the ability to develop into 
an endotheliallineage217• However the speculative advantages of "seeding" 
senescent, atherosclerotic capillary beds with such cells in a purported attempt 
to stimulate angiogenesis does not find conceptual favour in a non-ischaemic 
model. Taking a broader perspective, it is likely that a CD133+ subpopulation will 
be included in a CD34+ population anyway as their temporal changes in 
antigenic expression with developing maturity coincide218• 
Debate has occurred regarding the significance of the presence or absence of 
the CD34 antigen on haematopoietic stem cells. Cells described as lineage-
negative (Le. those lacking standard haemopoietic markers of maturity including 
CD34) have been shown to engraft in sheep and murine models. Cells exhibiting 
low surface CD34+ expression have been shown to migrate to bone marrow 
where they then appear to express CD34 and become able to engraft secondary 
recipients over the longer term, thus supporting the notion that CD34 may be an 
activation marker. However, such lineage-negative populations are extremely 
rare, require ex vivo expansion with liquid cultures and are at present clinically 
impractical. 
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We took a more practical pathway, committing to clinically-relevant quantities of 
material by using a lineage negative population depleted of mature 
haematopoietic cells, enriched for haematopoietic progenitors and also 
containing mesenchymal stem cells. From this we derived an easily handled, 
compact cell product that could be easily injected into the myocardium. From a 
cardiac perspective, CD34+ cells have been shown to exhibit superior efficacy in 
preserving myocardial integrity and function after myocardial infarction 
compared to unselected circulating mononuclear cells219 and in a dose-
dependent manner20,221, 
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3.2 Cord blood stem cell isolation from normal pregnancies and 
children with Hypoplastic left heart syndrome 
As a prelude to xenotransplantation trials and also to build a bank of control data 
with which to compare cord blood stem cells obtained from pregnancies with 
congenital heart disease, I set out to obtain, characterise and store several 
normal human cord blood samples. 
Prior to this, I undertook exploratory work looking at the feasibility of obtaining 
and using porcine or ovine cord blood in lieu of human blood. This proved 
logistically difficult and should I have pursued this further, this would have been 
hampered by a lack of cell surface antibody markers. Existing laboratory 
protocols and expertise made the use of human cells a logical choice and would 
also facilitate the detection of transplanted cells by exploiting their human 
characteristics detectable by PCR and antibody-based methodology. 
Current understanding regarding the aetiology of clinically-recognisable and 
significant forms of congenital heart disease is characterised by a relative 
paucity of recognised single genetic defects. Many anomalies are thought to 
result from subtle mutations in regulators of heart development causing 
dysregulation in key transcription factor pathways in association with disturbed 
epigenetic phenomena such as hydraulic flow222• Therefore autologous stem 
cells with as yet undefined defective genotype may be suboptimal for use in 
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attempting to bring about favourable cardiac adaptations to increased 
haemodynamic load. 
This report details the cell populations characterised in freshly-collected human 
cord blood samples. Analysed samples were selected from a pool of intact cord 
blood units, not rejects from cell therapy protocols nor cultured populations, 
which should be borne in mind when considering cell numbers for example. 
Cryopreserved cells were then subsequently used in a xenotransplantation 
neonatal model investigating the potential enhancement of right ventricular 
function in response to increased workload. 
The aims of this work were several: to gain expertise in handling the materials, 
to establish a database of normal subject data, create a cryopreserved cells for 
later use in xenotransplantation experiments and also to compare the 
phenotype and enumeration and short-term culture potential of cord blood from 
normal subjects with that from children with HLHS. 
91 
3.2.1 Methods 
Informed consent was obtained from cord blood donors. Protocols were 
approved by the ethics review boards of the Royal Women's Hospital and the 
Murdoch Children's Reserch Institute, Melbourne, Australia. 
Fresh human umbilical cord blood was obtained at delivery from consenting 
mothers with children with HLHS and processed within 12 hours of collection. 
Umbilical cord blood was diluted 1:2 with sterile phosphate buffered saline and 
mononuclear cells obtained by density centrifugation at 1 ,800rpm for 20 min 
(Ficoll-Paque Plus; Invitrogen) and ammonium chloride lysis. The mononuclear 
cell fraction was collected, counted using tryphan blue exclusion and 
haemocytometry and 1 x1 06 cells put to one side for later use in the mononuclear 
cell culture plate (Figure 3.2.1). 
A progenitor-enriched fraction was then obtained using immunomagnetic lineage 
depletion (StemSep®; StemCell Technologies). Cells were counted using 
tryphan blue and manual haemocytometry. Representative samples of both 
unenriched and enriched cell suspensions were characterised using flow 
cytometry and three-colour combinations of monoclonal antibodies conjugated to 
fluorescein isothiocyanate, phycorythrin or allophycocyanin (antibodies: human 
C033, C034, C038, C045) and using matched isotype-stained controls (all 
Becton Dickinson Biosciences, San Jose, CA, USA) to establish gates and 7-
amino-actinomycin 0 (7-AAO) for assessment of cellular viability (Figure 3.2.2). 
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At least 50,000 cells were acquired with a LSR II® flow cytometer and analysed 
using FACSDiva software (both 80). 
Growth potential of mononuclear and progenitor-enriched cells was also 
assessed These were performed using commercially available culture medium 
and protocol (MethoCult H4434, StemCell Technologies, Vancouver, Canada). 
Mononuclear and progenitor-enriched cells were plated separately in duplicate 
and cultured for 14 days at 37°C in a humidified atmosphere with 5% carbon 
dioxide. 5 x 103 cells were used in each well. Colonies were counted after this 
period according to their morphological characteristics by a single, experienced 
observer (N. Elwood) and results expressed as colonies per 1000 cells plated. 
3.3 Results 
Flow cytometric analysis of normal cord blood samples 
Flow cytometric analysis of standard lymphocyte gates of cord blood cell 
populations revealed a forward and side scatter characteristic of cord blood 
cells. The viability of these gated cells, as determined by 7-AAD was 94% ± 2.5. 
Cells within the gate were then subphenotyped by CD34, CD45 and CD33/38 
expression (Figure 3.3.1 A to D). Immunomagnetic negative selection resulted in 
a mean enrichment of CD34+/CD45+ cells of 28.0 fold (see Figure 3.3.2). The 
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results of enumeration and phenotyping of normal cord blood units are shown in 
table 3.3.1. 
Table 3.3.1 Summary of cell surface phenotyping studies on enriched cell 
populations (n= 50) 
Surface markers % number 
C034+ Mean 57.9 2.S7E+OS 
SO 9.2 S.11 E+OS 
Median 55.9 2.B4E+OS 
C034- 42.1 2.02E+OS 
9.2 7.90E+OS 
44.1 1.7SE+OS 
C034+C04S+ 59.2 2.72E+OS 
11.S S.32E+OS 
57.4 2.B4E+OS 
C034+ C04S- 0.4 1.94E+04 
0.4 1.7SE+04 
0.2 1.13E+04 
C034+ C033+ C03B+ 36.8 1.77E+06 
19.0 1.0BE+06 
46.3 1.BOE+06 
CD34+ CD33- C03B- 28.4 1.27E+06 
24.3 1.0SE+OS 
16.9 7.1SE+OS 
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Surface markers % number 
CD34- CD45+ 37.8 1.79E+06 
11.1 6.81 E+05 
37.2 1.52E+06 
CD34- CD45- 6.7 3.26E+05 
4.4 2.38E+05 
6.2 2.73E+05 
CD45+ 91.8 4.30E+06 
6.6 9.48E+05 
92.5 4.11E+06 
CD45- 8.2 3.92E+05 
6.6 3.01E+05 
7.6 3.35E+05 
Comparison of normal and HLHS cord blood units 
50 normal cord blood units were collected and analysed, all within 4 hours of 
collection. Within the same time period, 8 units from HLHS births were collected. 
Using the data from the normal database, the flow cytometry results of the 8 
HLHS samples were compared. For each of the markers of interest, frequency 
distributions were plotted of cell surface phenotypes, using 8 gestational-age 
matched controls for the 8 HLHS cord blood samples (Figure 3.3.3). 
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There were no significant differences between the two groups, either for number, 
cellular viability as assessed by 7-AAD or cell phenotypical classification (Tables 
3.3.2 and 3.3.3). 
Table 3.3.2 Comparison of cell number and viability between normal and 
HLHS-derived cord blood units 
Normal HLHS P 
(n = 50) (n =8) t test 
Number and viability 
Number of mononuclear cells 
(x 108) 3.3 ± 1.7 3.4 ± 2.5 NS 
Number of Lin- cells (x 106) 4.9 ± 1.3 4.7 ±2.0 NS 
Viability (%) 94 ± 2.5 94 ± 2.1 NS 
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Table 3.3.3 Comparison of cell phenotype and number between normal and 
HLHS cord blood units 
Normal HLHS 
(n=50) (n=8) t test 
CD34+ (%) 57.9 ± 9 (56) 57:t 13 (58) NS 
2.7 ±0.5 
absolute cell number x 106 (2.8) 2.6 ± 1.6 (2.8) NS 
CD34- (%) 
absolute cell number x 106 
CD34+ I CD45+ (%) 
absolute cell number x 106 
CD34+ I CD45- (%) 
absolute cell number x1 04 
CD34+ I CD33+ I CD38+ 
42.1 ± 9 (44) 43:t 15 (42) 
2.0 ±0.8 
(1.7) 
59.2 ± 12 
(57) 
2.7 ±0.5 
(2.8) 
0.4 ± 0.4 
(0.2) 
1.9 ± 1.8 
(1.1 ) 
2.1 ± 1.3 (1.9) 
57 ± 16 (58) 
2.6 ± 0.9 (2.8) 
0.4 ±0.8 
(0.25) 
1.7±1.8(1.2) 
NS 
NS 
NS 
NS 
NS 
NS 
(%) 36 ± 19 (46) 37:t 21 (47) NS 
1.8 ± 1.1 
absolute cell number x 106 (1.8) 1.7 ± 1.9 (1.8) NS 
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Normal HLHS t test 
CD34+ / CD33-1 CD38- (%) 28.4 ± 24 (17) 37 ± 27 (47) NS 
absolute cell number x 106 
CD34-1 CD45+ (%) 
absolute cell number x 106 
CD34-1 CD45- (%) 
absolute cell number x1 05 
CD45+ (%) 
absolute cell number x 1 06 
CD45- (%) 
absolute cell number x1 05 
1.3 ± 1.0 (0.7) 1 .2 ± 2.1 (0.7) NS 
37.8 ± 11 (37) 39 ± 14 (38) NS 
1.8 ±0.7 (1.5) 1.8 ± 1.4 (1.6) NS 
6.7 ± 4.4 (6.2) 6.3 ± 6.6 (4.8) NS 
3.3 ± 2.4 (2.7) 2.9 ± 3.4 (2.2) NS 
91.8 ± 6.6 (93) 94 ± 7.9 (94) NS 
4.3 ± 0.95 (4.1) 4.2 ± 1.1 (4.2) NS 
8.2 ± 6.6 (7.6) 6.1 ± 4.5 (6.7) NS 
3.9 ± 3.0 (3.4) 2.7 ± 4.6 (2.5) NS 
All data expressed as mean ± SD (median) 
% shown is percentage of lineage negative population 
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Methocult colony forming assay culture 
There was no evidence of tumour formation, dysregulated growth or monoclonal 
expansions. 
Table 3.3. Colony enumeration 
Lin- Normal HLHS Expected 
n=8 n=8 
CFU-E 13 24 9 
(0-28) (0-49) (1-48) 
BFU-E* 0 0 104 
(1-310) 
CFU-GM 128 88 115 
(0-284) (0-212) (1-303) 
CFU-GEMM 72 58 25 
(0-127) (0-199) (1-59) 
Mean number of colonies per 105 cells plated 
Range derived from 2x standard deviations of mean 
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Legend: 
CFU-E 
BFU-E 
Colony-forming unit-erythroid, mature erythroid progenitors that 
require erythropoietin (EPO) for differentiation. 
Burst-forming unit-erythroid, more immature progenitors than 
CFU-E. Their low number in this context was to be expected as 
the immunomagnetic lineage depletion protocol should have 
depleted such cells. 
CFU-GM Colony-forming unit-granulocyte, macrophage. Composed of 
~ 2 0 0 granulocytes (CFU-G), macrophages (CFU-M) or cells of 
both lineages (CFU-GM). 
CFU-GEMM Multi-potential progenitor that produces a colony containing 
erythroblasts and cells of at least two other recognizable 
lineages. 
Colony assays were unfortunately hampered by a small sample size and a wide 
range of "normal" expected values. In the limited data to hand, HLHS cord blood 
units appeared to have relatively fewer CFU-GMs and CFU-GEMMs compared 
to normal cord blood. 
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3.4 Discussion 
Both mononuclear cells and the lineage negative fraction of cord blood stem 
cells obtained from children with HLHS are similar in number and phenotypic 
enumeration to normal cord blood. 
The results of short-term in vitro culture to investigate the relative growth 
potential of the two sample groups were inconclusive. Only 8 cord blood 
samples from HLHS children were processed to date during which time I was 
probably in the learning curve of the technique and might have been prone to 
operator error. 
Umbilical cord blood proved easy to handle and with reproducible cell isolation 
under sterile conditions coupled with controlled freezing with cryoprotectants, 
umbilical cord blood warrants further examination as a cell therapy in congenital 
heart disease. 
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3.5 Figures 
Figure 3.2.1 Example of mononuclear cell count using haemocytometer 
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Figure 3.2.2 Example of cellular viability of freshly-collected cord blood 
mononuclear cells processed within 4 hours of collection using 
7-AAD 
7MD-A 7MD-A 
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Figure 3.3.1 Representative flow cytometric analysis of enriched CB 
populations showing forward versus sideward scatter plot and 
gating (A). The proportion of gated CD34/CD45 cells is shown in 
(B) , CD34/CD33 and CD38 cells in (C) and CD45/CD33 and 
CD38 cells in (D) . 
A B 
~ ~ 100 1 ~ ~ WO 2 ~ ~
FSC-A (x 1.000) 
C o 
. 1 1 ~ ~ 1 1
o 10° 
C033/3S 
Figure 3.3.2 Example flow cytometric analysis showing effects of 
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Figure 3.3.3 Frequency distribution of cell surface phenotypes, using 8 
gestational-age matched controls and 8 HLHS cord blood samples 
(see following pages) 
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Figure 3.2. Colony photos 
Figure 3.2.a Erythroid colony 
Figure 3.2.b,c Mixed colonies at 2 weeks 
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Figure 3.2.d,e (x40) 
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Figure 3.2. Example of CFU-GEMM: Colony-forming unit-granulocyte, 
erythroid, macrophage, megakaryocyte (x10) 
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4.0 Transplanted human cord blood stem cells improve cardiac 
function in a neonatal ovine model of right ventricular training 
4.1 Abstract 
Non-ischaemic right ventricular dysfunction and cardiac failure is a source of 
considerable morbidity in children with congenital heart disease. Despite work in 
adult ischaemic heart disease, cell transplantation has not previously been 
studied in the paediatric setting where enhancing ventricular function in 
response to supraphysiological workloads might be beneficial. 
We transplanted human cord blood stem cells into an immunosuppressed 
neonatal sheep model of right ventricular training and took load-independent 
functional measurements at baseline and again after one month. 
Transplanted human cells were detected in the myocardium, spleen, kidney and 
bone marrow up to 6 weeks after transplantation. The cells identified expressed 
the haematopoietic marker CD45 and in the bone marrow and spleen, also the 
mature B cell marker CD23. We did not identify any differentiation into 
cardiomyocytes, myocytes nor other mesenchyme-derived tissues. Significant 
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functional improvements were seen in the group receiving human cord blood 
stem cells compared to placebo. 
Our data demonstrate that lineage negative-enriched cord blood stem cells 
engraft and augment right ventricular function. The cells adopt haematopoietic 
fates in both myocardium as well as the bone marrow and spleen. 
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4.2 Introduction 
Increased right ventricular workload is an important feature in several types of 
congenital heart disease, particularly where the right ventricle is the sole 
functioning ventricle or where it acts as the systemic ventricle in lieu of the left. 
Despite improvements in treatment, early and late right ventricular dysfunction 
and cardiac failure due to pressure or volume overload is a source of persistent 
morbidity in children with congenital heart disease contributing to reduced 
su rvivaI175,223-225. 
Cell transplantation has been shown to have beneficial effects on left ventricular 
function in anima1116,226 and human210,227-229 studies of ischaemic heart disease. 
It has been hypothesised that haematopoietic stem cells (HSC) or mesenchymal 
stem cells (MSC) transplanted into ischaemic myocardium may contribute to 
recovery by differentiation into de novo cardiomyocytes23o, reseeding damaged 
microvasculature, angioblast-mediated vasculogenesis or encouragement of 
endogenous reparative mechanisms by as yet incompletely-defined paracrine 
mechanisms153• Little is known about the potential of similar techniques to 
facilitate recovery in non-ischaemic heart disease or to augment adaptation of 
the systemic ventricle in younger age groups experiencing supraphysiological 
cardiac workloads due to congenital heart disease. It is likely that similar 
molecular mechanisms are at work in both embryonic and post-natal 
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cardiogenesis as well as regeneration of adult myocardium following ischaemic 
insults. Much as the recruitment or mimicry of regenerative processes in the 
adult heart offers therapeutic potential231 , enhancing adaptive responses to 
augment cardiac function in response to increased workload or non-ischaemic 
insults in the young heart may involve similar processes which could be similarly 
open to augmentation. 
Umbilical cord blood is readily-available and is a rich source of heterogeneous 
stem cell populations (CBSC) that are self-renewing, clonal precursors of both 
haematopoietic and non-haematopoietic tissues195. CBSCs have been well 
characterized through their clinical use in the treatment of haematological 
malignancies204-2o6. Ex vivo work has documented the ability of such cells to 
proliferate in culture and differentiate into a variety of cell types of differing 
Iineages195,2oo. Homing experiments have demonstrated that CBSCs can traffic 
through the intact human system to where they are required. Furthermore, 
lineage-negative cell fractions enriched for the expression of CD34 are able to 
engraft in ovine and murine models over the longer term. It may be in fact that 
an earlier stem cell type, rather than the committed haematopoietic stem cell, 
can be harvested from CB and BM to account for the increasingly wide range of 
cell types that can be developed from these cell sources. 
Transplantation of human CBSC into an immunosuppressed large animal model 
allows the detection of engraftment and evaluation of cell fate232. We used the 
immunosuppressed neonatal lamb model because of previous work in human 
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haemopoiesis, xenotransplantation and procedural experience within our group. 
In this model, long-term multi-lineage human chimerism has been 
established203• As human and sheep DNA and proteins differ significantly, 
human-specific markers can be used for unequivocal detection and 
characterisation of cells by independent yet complementary methodologies. 
We isolated and purified human umbilical cord stem cells and set out to test the 
hypothesis that human umbilical cord blood stem cells can enhance myocardial 
performance after transplantation into a neonatal ovine model of right ventricular 
training. Our results document retention of human cells in the pressure-
overloaded neonatal heart, expressing haematopoietic markers in association 
with improvements in systolic and diastolic function. 
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4.3 Methods 
4.3.1 Cord blood stem cell isolation 
Fresh umbilical cord blood was obtained for research purposes from consenting 
normal human donors shortly after delivery of healthy children >38 weeks 
gestation, with approval from the RCH Ethics in Human Research Committee. 
Cord blood stem I progenitor cells (CBSCs) were isolated and enriched using 
density centrifugation (Ficoll-Paque Plus; Invitrogen) and immunomagnetic 
lineage negative selection (StemSep; StemCell Technologies) 233. Cells were 
suspended in a mixture of Iscove's modified Oulbecco's medium (IMOM; 
Gibcove) and fetal bovine serum containing 5% dimethylsulfoxide and stored in 
vapour phase above liquid nitrogen. 
When required, cells were thawed and re-suspended in 500 pi of bovine serum 
albumin and dextran-40. Thawed CBSCs had an immediate mean viability of 
92.6 ± 2.6% as assessed by staining with 7-amino-actinomycin and flow 
cytometry. Flow cytometry was used to characterise cell populations (LSR II, 
antibodies: human CD33, C034, CD38, C045) and matched isotype-stained 
controls (all BO Biosciences, San Jose, CA, USA). The reconstituted final cell or 
placebo preparation into the right ventricular myocardium was transplanted by 
transepicardial injection using a 30-gauge needle. Placebo medium consisted of 
a 1:1 ratio of bovine serum albumin and dextran-40. 
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4.3.2 Animals 
Pregnant Border Leicester sheep of confirmed gestational age were housed in 
the large animal facility at a University of Melbourne. Lambs were born naturally 
and housed with their respective ewes. All lambs received 5 mg/kg/day oral 
cyclosporin solution (Neoral®, Novartis Pharmaceuticals pty Ltd, Australia), 
achieving mean whole blood trough cyclosporin concentrations of 168.7 I1g/1. 
All experimental protocols were approved by the Animal ethics committees of 
the Murdoch Children's Research Institute and the University of Melbourne and 
conducted in accordance with the "Australian code of practice for the care and 
use of animals for scientific purposes" (National Health and Medical Research 
Council, Australian Government, 7th edition, 2004). 
4.3.3 Invasive haemodynamics and pulmonary artery banding 
Neonatal sheep (mean age 10.0 ± 3.1 days; mean body weight 6.7 ± 1.5 kg) 
were anaesthetised and ventilated using a standardised protocol compriSing 2% 
inhalational isoflurane supplemented by buprenorphine, fentanyl and intercostal 
bupivacaine nerve blocks. Central venous and arterial catheters were placed, 
then 100 U/kg of unfractionated porcine heparin and atracurium administered. 
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A left thoracotomy was performed and cardiac catheterisation was performed via 
the right ventricular outflow tract. The patency of the ductal arteriosus was 
excluded, the inferior vena cava was dissected out immediately above the 
diaphragm and the circumference of the pulmonary artery measured 10mm 
distal to the pulmonary valve. 
We studied the functional effect and fate of human essc or inert carrier medium 
in 16 immunosuppressed neonatal sheep in whom the main pulmonary artery 
was banded; two other groups (n=6 each) received either carrier medium or cord 
blood stem cells without pulmonary banding to establish the effect of cell 
transplantation on cardiac developmental changes in the neonatal period. 
Haemodynamic indices were measured at baseline and again four weeks after 
initial surgery in placebo-treated (n=6), cell-treated (n=6), PAS and placebo 
treated (n=8) and PAS and cell treated animals (n=8) with a dual-
micromanometer pressure transducer and conductance catheter used in 
conjunction with a pressure signal amplifier (Millar Instruments, Houston, Texas, 
USA) and signal conditioner (CD Leycom, Zoetermeer, The Netherlands). 
Cardiac output was measured simultaneously using a non-occlusive 
perivascular ultrasonic flow probe (Transonics) placed around the pulmonary 
artery just distal to the pulmonary valve. Data were recorded at 1 kHz during 
steady state and transient periods of inferior vena caval occlusion and stored for 
off-line analysis using customised software (Spike2, Cambridge Electronic 
Design, UK). 
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Parallel conductance of the right ventricle was evaluated by using injections of 
hypertonic saline solution into the right atrium; slope factor121 was determined 
using cardiac output to allow for correction of volume measurements at post-hoc 
analysis. 
All animals underwent baseline haemodynamic studies followed by PAB, 
placebo or human cord blood stem cell injection, according to treatment 
allocation. Where applicable, a non-absorbable 3 mm-wide Dacron® band was 
placed around the pulmonary artery, empirically reducing the cross-sectional 
area of the native vessel by 30%. After 30 minutes, a series of 5 to 6 injections 
of human CBSes in 500pl (mean cell number 4.7 x 106) or an identical volume 
of non-human serum albumin and dextran-40 medium as a placebo, were made 
into the right ventricular wall, as demarcated by the left anterior descending 
artery, atrioventricular junction and posterior descending artery. Measuring 
devices were removed, the chest closed and animals weaned from the ventilator 
and extubated. All lambs received a four day course of prophylactic antibiotics 
post-operatively. 
4.3.4 Tissue processing 
Sheep were killed after repeat cardiac catheterisation one month following 
placebo or cell transplantation. Heart, liver, spleen, kidney and bone marrow 
samples were collected and analysed for the presence of human cells by DNA 
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isolation and immunohistochemistry. Tissue was fixed in 4% paraformaldehyde 
for 4 hrs, stored overnight in 30% sucrose with 0.1 M phosphate-buffered saline, 
pH 7.2, embedded in OCT and then stored at -aO°C. Additional samples from 
each tissue were frozen and stored in liquid nitrogen for subsequent total cellular 
DNA extraction. 
4.3.5 DNA extraction and peR analysis 
Total cellular DNA was extracted (DNeasy, Qiagen) and analysed by PCR for 
human-specific B-2 microglobulin. Specific primers for human B-2 microglobulin 
were selected based on the published human sequence (upstream primer, 5'-
GTGTCTGGGTTTCATCAATC-3'; downstream primer, 5'-
GGCAGGCATACTCATGTTTI-3') that was shown to selectively amplify human, 
not ovine DNA. All samples were also amplified to detect the B-actin gene 
(upstream primer, 5'-CGGGACCTGACTGACTAC-3'; downstream primer, 5'-
GAAGGAAGGCTGGAAGAG-3') as a control for presence of amplifiable DNA. 
Amplification conditions included initial denaturation at 95°C for 9 min followed 
by 45 cycles of denaturation at 95°C for 30s, annealing at 55°C for 30s, 
extension 72°C for 15s, followed by an final extension at 72°C for 5 min. PCR 
products were resolved by electrophoresis through 2% agarose gels containing 
ethidium bromide. The sensitivity of the assay was assessed by human/sheep 
dilution studies which established standard curves demonstrating a sensitivity of 
detection of 1 ng human DNA in 1,000 ng ovine DNA. 
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4.3.6 Immunohistochemistry 
Ovine heart, lung, liver, spleen, kidney, bone marrow and peripheral blood were 
screened for the presence of human cells by PCR. Tissues positive by PCR 
were then analysed by immunohistochemistry to investigate cell fate. Tissues 
negative by PCR and from control group sheep were used as negative controls. 
Cells isolated from the buffy coat of ovine peripheral blood was also analysed 
using flow cytometry for human haematopoietic and stem cell markers. 
Staining was performed for human nuclear antigen, human CD23, CD34, CD45, 
human sarcomeric smooth muscle actin, SERCA-2, connexin-43, human myosin 
heavy chain, sarcomeric smooth muscle actin, N-cadherin, vimentin, cytokeratin-
18, Nkx2.5, ,and von Wille brand Factor. Serial cutting sections 10 pm in 
thickness were taken from each of the OCT-embedded tissues and placed on 
Superfrost Plus slides (Menzel-Glaser). To enhance antigen retrieval, slides 
were heated at 90°C for 10 minutes in 10 mmol/L citrate buffer (pH 6.0) and 
washed in phosphate buffered saline. Sections were then blocked in non-
immune serum from the species in which the primary antibody was raised, 
followed by 14 hours incubation with primary antibodies. After incubation slides 
were rinsed with PBS and secondary detection performed using appropriate 
fluorescent antibodies (Jackson Immunoresearch) or a chromagen-based 
biotinylated antibody kit (Vectastain ABC kit; Vector Laboratories). 
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4.3.7 In situ hybridization 
Antigen retrieval was performed as described above. A fluorescein-conjugated 
human ALU probe (Innogenex, San Ramon, California) was applied and 
hybridization was done at BO°C for 5 min, followed by overnight incubation at 
37°C. Slides were developed using an in situ hybridization kit for fluorescein-
labelled probes (Innogenex) with DAB used as a substrate to develop the stain. 
For cardiac sections, in situ hybridization was done before staining with other 
primary antibodies as required. 
4.3.8 Statistical analysis 
Between-group differences were examined using analysis of variance testing. P 
values of less than 0.05 were considered significant. All P values are two-sided. 
124 
4.4 Results 
4.4. 1 Cell isolation and purification 
CBSCs were isolated from freshly-collected human umbilical cord blood and 
stored in liquid nitrogen until required. Mononuclear cell yields per cord blood 
unit before and after immunomagnetic lineage depletion were 3.3 x 108 ± 1 .6 x 
108 and 4.7 x 106 ± 1.0 X106, respectively. Cellular viability of the final cell 
product following thawing was 93.6% ± 2.3 (94%). There were no significant 
differences in viability between samples used for group 2 or 4 (93.6 ± 2.5% vs. 
93.7 ± 2.1%). Greater than 90% of lineage negative cells were CD45+ and 6 to 
8% (3.5x105) CD45·. An average of 58% of all cells were CD34+; of which half 
were CD33+/CD38+ committed progenitor cells and half CD33-/CD38- primitive 
haematopoietic stem cells 234. Of the CD34- cells, the majority were CD45+ and 
therefore haematopoietic in lineage. There were no statistically significant 
differences in number, viability nor phenotype between cells injected into the two 
groups of sheep receiving stem cell treatment in the xenotransplantation model. 
4.4.2 Transplanted CBSCs distribute to cardiac and non-cardiac tissues 
We assessed the in vivo effects of CBSC transplantation by injecting 4.7 x 106 
hCBSC into the right ventricle of week-old neonatal sheep 30 mins after 
pulmonary artery banding (PAS) (Figure 4.1). We chose this age as this is a 
common time for the surgical intervention for the most therapeutically-
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challenging forms of congenital heart disease. 28 sheep were studied, all of 
whom were immunosuppressed. 
One month after in vivo injection we screened tissues by PCR for human-
specific B2-microglobulin DNA to investigate the presence and distribution of 
viable human cells. All 14 transplanted sheep had detectable human cells in the 
right ventricle at one month. These cells were located either in isolation or small 
clusters of 3 to 5 cells throughout the pressure-loaded tissue. Transplanted cells 
were also detected in a variable fashion in non-cardiac tissues including lung, 
liver, bone marrow, spleen and kidney (Figure 4.2a, 4.2b; Table 4.1). Peripheral 
blood samples were negative for human-specfic DNA sequences or 
haemotopietic markers by PCR and flow cytometry, respectively. These results 
support a model of haematogenous distribution. 
Following epicardial injection, some of the heterogeneous populations of CBSCs 
remained local to the site of injections with a proportion distributed systemically, 
migrating across endothelial barriers, to take up residence within organ-specific 
microenvironments and achieve survival at one month. The pattern of 
distribution in extra-cardiac tissues might be indicative of the distributive effects 
of the bloodstream once cells had passed back into the left side of the heart or 
the relationship between the pre-determined fate of transplanted cells and the 
various host tissues providing specific and favourable microenvironments. 
Transplanted xenogeneic cells may have also temporarily integrated into other 
tissues but lacked the ability to survive. We did not attempt a detailed 
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quantification of the number of human cells surviving or proliferating one month 
after transplantation. The total number of human cells within the right ventricle 
was estimated in a subset of animals. 0.07% of all nuclei examined in the right 
ventricular free wall were of human origin at 30 days. On first impression this 
frequency of donor cells may be considered disappointing, but this must be 
considered in light of the near-exponential somatic growth that occurs in the 
neonatal phase of large animal models and also by the results of quantitative 
xenogeneic studies of haematopietic cell turnover in chimeric bone marrow that 
have demonstrated significant expansion in the total number of donor cells 
following transplantation despite detection of similarly low frequencies of donor 
cells 235. 
To confirm the presence of human cells in PeR-positive tissues, we stained 
sections with an antibody specific for buman nuclear antigen, a human-specific 
nuclear component (Figures 4.3a-d) and performed in situ hybridisation studies 
using a human-specific Arthrobacter luteus (Alu) gene probe (Figures 4.4a-d). 
Human cells were found in injected hearts in a scattered pattern as rare events 
in the right ventricular free wall. We also identified cells positive for human 
nuclear antigen, principally in the perivascular regions, in the kidney, bone 
marrow and spleen, all tissues with haematopoietic or lymphopoietic roles 
(Figures 4.3b-d). Negative controls, consisting of tissues from transplanted 
sheep that were negative by peR and tissues from normal sheep, were 
uniformly negative and confirmed the human specificity of the staining methods. 
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4.4.3 Transplanted CBSCs express CD45 in cardiac tissue 
We evaluated the fate of transplanted cells in both cardiac and non-cardiac 
tissues using a combination of approaches. Double- and triple-staining 
immunofluorescent or immunohistochemical antibody techniques were used 
incorporating an antibody against human nuclear antigen or a human Alu probe 
combined with a panel both human-specific and non-human-specific 
differentiation markers to investigate the fate of the transplanted human cells. 
Cardiac tissue was stained with antibodies against myofibrillar components 
human cardiac myosin, skeletal myosin and human troponin, smooth muscle 
actin, smooth endoplasmic reticulum ATPase-2 (SERCA-2), connexin-43 and 
Nkx2.5, as well as von Willebrand Factor (vWF), a marker for endothelial cells. 
Human cells located in the myocardium were found to be CD45 positive 
suggesting that these cells were from a haematopoietic fraction of the enriched 
cord blood (Figure 4.5). We found no evidence to support transdifferentiation of 
transplanted human cells in the sheep myocardium. Specifically, human cells did 
not co-localise with contractile filaments nor exhibit positivity for mesenchymal 
markers. 
4.4.4 CD45-positive or CD23-positive transplanted CBSCs identified in 
non-cardiac tissue 
We then further characterised human cells identified in sections of kidney, bone 
marrow and spleen. Human cells in the kidney stained positively for CD45, 
demonstrating a haematopoietic fate one month after injection (Figure 4.6). 
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Staining of these human cells with antibodies against CD23, a marker of a-cell 
progenitors and bone marrow stromal cells, endothelial and mesenchyal 
markers was consistently negative. One month after transplantation, several 
clusters of human cells strongly expressing CD45 and human nuclear antigen or 
human CD23 were present in the marrow and spleen (Figures 4.7a, 4.7b, 4.8a, 
4.8b). Human cells in sheep bone marrow or spleen were positive for either 
CD45 or CD23, simultaneous co-expression of these markers was not seen. 
This suggests that least two distinct populations of human cells had taken up 
residence or matured in haematopoietic and lymphopoietic tissues within the 
host animal. Although human cells were identified by PCR in the liver and lung 
tissue of four transplanted animals, they could not be located on sections by our 
immunohistochemical and immunofluorescent methods. Finally, there was no 
evidence of uncontrolled growth or inflammatory infiltrate in any of the examined 
sections 
4.4.5 Intramyocardial ease injection enhances right ventricular systolic 
function in the presence of increased after/oad 
We studied the functional effect and fate of human casc or inert carrier medium 
on right ventricular function in 16 immunosuppressed neonatal sheep in whom 
the main pulmonary artery was banded with either casc or carrier medium 
injection; two other groups (n=6 each) received either carrier medium or cord 
blood stem cells without pulmonary banding to establish the effect of cell 
transplantation on cardiac developmental changes in the neonatal period. 
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Load-independent functional indices were measured at baseline and again four 
weeks later. Baseline variables of right ventricular function, pressures and 
volumes did not differ significantly between the four groups (Table S2, 
supplementary data). 
One month after initial functional assessment, right ventricular performance was 
found to be slightly reduced in the control group, consistent with expected post-
natal changes that include decreased beta-adrenoceptor expression. 
Transplantation of CBSCs without pulmonary artery banding had no significant 
effects on haemodynamic variables and load-independent indices of systolic and 
diastolic function. 
One month following pulmonary artery banding and placebo injection, we 
observed improvements in load-independent indices of systolic function in the 
animals. Intramyocardial injection of CBSe with pulmonary artery banding was 
accompanied by improvements in systolic function greater than that of 
pulmonary artery banding alone (Figures 4.9a, 4.9b, 4.9c). 
Load-independent indices of right ventricular systolic function were significantly 
greater in group 4 receiving stem cells and pulmonary artery banding group 
compared with group 3 who received pulmonary artery banding and placebo; in 
groups 4 and 3 respectively, end systolic elastance (Ees) increased by a mean 
of 1.4 ± 0.2 mmHg/ml compared to 0.9 ± 0.1 mmHg/ml P<O.001; the slope of 
preload recruitable stroke work (Mw) increased by 21.1 ± 2.9 mmHg compared 
to 15.8 ± 2.5 mmHg, P<O.05; the slope of the relation between dP/dtMAX and 
130 
end diastolic volume ([dP/dtmax]edv) 17.3 ± 2.2 mmHg/s/ml compared to 11.6 ± 
1.6 mmHg/s/ml, P=O.06). 
4.4.6 casc transplantation improves diastolic function 
At four weeks, diastolic parameters tended to be improved, albeit non-
significantly, in animals receiving PAS and esse injection compared to PAS 
and placebo injection. These two groups both had increases in right ventricular 
mass as expected in response to pulmonary artery banding. tau, the time 
constant of relaxation, increased by 8.7 ± 5.7 ms in the group receiving esse 
compared to 13.2 ± 6.2 ms in the group receiving placebo (P>O.05). These 
observations of improved relaxation and reduced myocardial stiffness may 
·indicate that esse encourage a more beneficial and less restrictive growth 
response to increased afterload characterised by relatively reduced myocardial 
interstitial oedema and consequently less fibrosis, a chain of events recognised 
clinically236,237. 
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4.5 Discussion 
We have shown here that transplanted human cells can be detected in the 
myocardium, spleen, kidney and bone marrow up to 6 weeks after 
transplantation. Human cells identified in the heart and kidney adopted a 
haematopoietic fate expressing CD45; in the bone marrow and spleen cells also 
expressed the mature B cell marker CD23. We did not identify any differentiation 
into cardiomyocytes, myocytes nor other mesenchyme-derived tissues. 
Our data demonstrates that lineage negative-enriched cord blood stem cells 
adopt haematopoietic cell fates in the myocardium where their presence 
augments right ventricular function in the presence of increased afterload. 
Following intramyocardial injection into the neonatal heart, viable transplanted 
cells are distributed systemically and take up residence in natural 
haematopoietic niches such as bone marrow and spleen and also migrate to 
distant tissues. 
The novel findings of this work demonstrate that intramyocardial injection of 
human cord blood stem cells enhances right ventricular function following 
pressure overload beyond functional responses to pulmonary artery banding 
alone. Trends in diastolic performance, although not significant, indicate that a 
more desirable adaptation was stimulated with improved relaxation indices 
compared to the banding alone. Interstitial oedema developing in the 
myocardium following acute pulmonary artery banding has been shown to 
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evolve into fibrotic tissue resulting in a stiffer, physiologically more restrictive 
ventricle.236,237 
These results show that CBSCs can be transplanted and are capable of 
integrating in multiple tissues, requiring migration across endothelial barriers and 
integration into host tissue microenvironments. This supports a model of 
haematogenous distribution, with subsequent selective survival in specific and 
appropriate tissue niches. These findings suggest myocardial retention of a 
small number of cells, followed by trafficking of other cells to tissues either along 
ontologically pre-determined positions or by virtue of haematogenous 
distribution. This may be a function of the ability of specific microenvironments to 
support the engraftment and differentiation of CBSCs; alternatively the lack of 
engraftment in some tissues may be due to heterogeneity of the transplanted 
cell population with respect to differentiation potential, replicative capacity or 
longevity. A third possibility is that the xenogeneic microenvironment can 
support the viability and differentiation of human CBSCs, but not their self-
replication. Although insufficient homing of cells, among other factors, could 
account for the lack of proper transdifferentiation, our study suggests a biological 
effect on right ventricular function and adaptation to increased loading 
conditions. Potential mechanisms for this beneficial effect include paracrine-
mediated effects by transplanted cells. 
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We have not quantitatively assessed expansion of the cells transplanted in this 
experiment. Minimal expansion of donor cells in this xenogeneic model would 
not be unexpected. However, the apparent low frequency of donor cells 
indicated by immunohistochemistry here may be misleading. This data should 
be interpreted with caution as cell division or proliferation of transplanted cells 
after intramyocardial injection may occur in the early time period. However, over 
time, most of the locally-delivered cells in each group examined either die or 
migrate elsewhere.ln this neonatal sheep model, rapid growth of the sheep 
occurred in the first month after transplantation (typically 75% increase in 
bodyweight) . 
Experiments in the sheep model of human haematopoiesis in which human cells 
have been quantitatively assessed in chimeric bone marrow have shown that 
even when low frequencies of donor cells can be detected, there is tremendous 
interval expansion in the total number of donor cells since transplantation. While 
0.07% represents only low-level engraftment, this does represent a significant 
number of cells, for example a year-old lamb is estimated to contain 1 .5 kg of 
bone marrow with 1 mg being equivalent to one million cells. In comparison, it 
has previously been shown with 67 000 human cord blood CD34+ cells that 2% 
to 3% chimerism was typical238• 
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Although we found no evidence of myocardial transformation in cell-treated 
hearts, we hypothesized that cell treatment could still have positive effects on 
cardiac geometry, mass acquisition and function after pulmonary artery banding. 
Our study had several limitations. Questions about responsible cell type, 
optimum dose, and timing of cell transfer still remain. We transferred cells 30 
mins after pulmonary artery banding. In many respects, the clinical utility of such 
an approach is needed, after all bone marrow transplantation has been 
performed using an unrarefied buffy coat fraction for many years and the precise 
cellular dynamics and transplantation kinetics are still being elucidated. 
CD34+ cells have been shown to exhibit superior efficacy in preserving 
myocardial integrity and function after myocardial infarction compared to 
unselected circulating mononuclear cells219 and in a dose-dependent 
m a n n e ~ 2 0 , 2 2 1 . . From a practical perspective, a mixture of mutually supportive 
heterogeneous cell populations is probably preferable to using a population far 
more purified and smaller in number. We therefore took a more practical 
approach, committing to clinically-relevant quantities of material by using a 
lineage negative population depleted of mature haematopoietic cells and 
enriched for haematopoietic progenitor cells. From this we derived an easily 
handled, compact cell product that could be easily injected into the myocardium. 
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The predictable adoption of mature haematopoietic fates of transplanted CBSCs 
supports the potential of these cells in cardiac transplantation and tissue 
engineering applications. Further insight is required into the normal and disease-
induced regulation of cell populations contained within CBSC, a greater insight 
into their transplant immunology and the development of strategies for diffuse or 
site-specific delivery for therapeutic applications. 
4.5.1 Conclusion 
Cell transplantation with human CBSCs provides some short- to mid-term 
benefit in enhancing right ventricular function in response to increased workload. 
These findings suggest the potential therapeutic use of cord blood stem cells to 
augment myocardial function in paediatric and non-ischaemic heart disease. 
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4.6 Figures 
Figure 4.1 Trial design 
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Figure 4.2a Screening of sheep tissues one month after transplantation, by 
DNA peR using probes specific for human B-2 microglobulin sequences. B-
actin lanes demonstrate presence of amplifiable DNA. 
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Figure 4.2b Serial dilutions of genomic human DNA in sheep DNA to establish 
sensitivity of DNA screening test with molecular size markers in right-hand lane 
(100 base-pair ladder) 
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Table 4.1 Frequency and distribution of human-sequence-positive tissues 
one month following injection, by DNA peR using probes specific for human B-2 
microglobulin sequences. 
eBse injection PA banding All 
and 
eBse injection 
(Group 2) (Group 4) 
n 6 8 14 
RV - Right ventricle 6/6 8/8 14/14 
LV - Left ventricle 216 3/8 5114 
Lu - Lung 116 1/8 2114 
Liv - Liver 0/6 2/8 2114 
Spl- Spleen 0/6 218 2/14 
Kid - Kidney 5/6 7/8 12/14 
BM - Bone marrow 316 5/8 8/14 
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Figure 4.3 Immunohistochemistry for Human Nuclear Antigen. 
A Right ventricle 
B Kidney 
C Spleen 
o Bone marrow 
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Figure 4.4 Immunohistochemistry for human-specific Alu gene 
o • 
A Right ventricle 
B Kidney 
C Spleen 
D Bone marrow 
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Figure 4.9a 
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Figure 4.9b 
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Figure 4.9c 
dP/dtMax EDV absolute change; mean and 95% Cis 
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5.0 Conclusion 
The dawn of the molecular scientific era has improved mechanistic insight into 
the intricacies of the stressed or failing heart in both paediatric and adult heart 
disease. A complex cocktail of subtle genetiC mutations, transcriptional 
pathways and checkpoints combine with epigenetic influences to manifest as 
clinical phenotypes. Ischaemic heart disease is one of the leading causes of 
death in adults and congenital heart disease is the largest non-infectious cause 
of death in children. The development of stem cell biology and the 
complementary field of regenerative medicine in cardiovascular medicine has 
captivated many scientists and members of the public alike. 
Attempts at myocardial augmentation or regeneration by harnessing or 
stimulating the heart's intrinsic regenerative capacity remains in their infancy. 
Functional improvements brought about my cell transplantation in acute animal 
models of ischaemic heart disease have not infrequently only translated into 
single digit improvements in left ventricular ejection fraction. Indeed, given the 
sheer global burden of ischaemic heart disease and the lack of evidence for 
differentiation or mechanical contribution of exogenous stem cells into 
myocardium, a cocktail of growth factors delivered locally into the myocardium, 
may prove more a viable approach than a tailor-made cell therapy. 
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At present, I believe the transplantation of stem cells or progenitor cells for 
purported paracrine effects remains a justifiable within the context of a trial given 
that multiple factors are likely to be functioning synergistically. Paracrine factors, 
either eluted from transplanted cells or introduced directly in a concentrated and 
refined form, could promote a shift in cardiac homeostasis encouraging cell 
survival and replication. Where hereditary considerations may exist, for example 
in congenital heart disease, autologous cells might not be desirable as 
repopulating a damaged organ with the same genotype is conceptually flawed. 
Allogeneic cells that can be processed to a high level of quality control and 
stored ready for 'off the shelf' are one possibility. If it is proven that paracrine 
cell-derived factors are indeed responsible for improvements in cardiac function, 
then protein-based therapy might be more clinically and logistically viable than a 
cell-based therapy. 
Whilst some would contend that there is no place for clinical trials on imperfectly 
understood science, I would disagree. In fact medical history is testament to the 
use of incompletely understood therapies being employed effectively, for 
example Edward Jenner and smallpox vaccination or bone marrow 
transplantation, in the latter the responsible cell type and kinetics took years to 
clarify. If we wait for every single nuance regarding a new treatment or drug to 
be clearly defined, we would be denying potentially life-saving treatments that 
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are already in wide-spread use. Such enthusiasm should be tempered by the 
potential pit-falls of accelerating too soon which could resemble the 
uncomfortable fanfare with which gene therapy arrived a decade ago and has 
since failed to deliver. Many questions remain regarding the optimal cell type, 
number, method of delivery and mode of action. The recent development of in 
vivo cell tracking technology has facilitated more meaningful studies looking at 
transplantation kinetics. 
This experimental work has shown that the right ventricular myocardium in 
hypoplastic left heart syndrome may be at an inherent disadvantage structurally 
and in terms of mounting an appropriate genetic response to generate sufficient 
haemodynamic force to sustain the circulation as a whole. 
I have also demonstrated a novel proof of concept using human umbilical cord 
blood stem cells in a clinically-relevant neonatal large animal model of right 
ventricular training and cellular xenotransplantation. Cell therapy has the 
potential to assist myocardial adaptation to supraphysiological loads and 
deserves further investigation. 
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In the future, I would like to examine in closer detail the viral cardiomyopathies 
and also more genetically-subtle small animal models of congenital heart 
disease. In the former, I postulate that the homeostatic balance of the myocyte 
mass becomes disturbed secondary to a viral infection and the occurrence of 
molecular mimicry. It is conceivable that stem cell transplantation in this situation 
could stimulate the recovery of resident stem cell activity and myocyte cycling. 
The latter offer an improvement of traditional lethality models and I would like to 
attempt stem cell "rescue" of Id mice or similar knock-out strain prone to cardiac 
defects using haematopoietic stem cells from normal and HLHS pregnancies. 
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6.0 Supplementary data 
Figure S2.1 Diagrams summarising the typical sequence of palliative surgery 
performed for HLHS 
Stage 1 Modified Norwood Operationn 
~ - - r - - Neoaorta 
Right atrium - r - ~ - R V - P A A conduit 
Usually performed in the first week of life and aims to create 
unobstructed outflow to the systemic circulation and well-balanced 
systemic and pulmonary circulations. The atrial septum is excised 
to allow unrestricted pulmonary venous return to the single 
morphological ventricle. The pulmonary artery is anastomosed to 
the native hypoplastic aorta which is typically reconstructed using 
a patch of homograft material. A shunt from the right ventricle to 
the pulmonary arteries provides pulmonary blood flow. 
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Stage 2 Bidirectional cavopulmonary shunt 
Generally performed on infants between 3 and 6 months of age. 
The superior vena cava is anastomosed to the ipsilateral 
pulmonary artery so that systemic venous return from the head 
and neck returns to the pulmonary circulation directly. This reduces 
the volume load on the single ventricle 
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Stage 3 Extra-cardiac Fontan 
This completes the reconstructive surgery for HLHS and is 
performed around 5 years of age. A Gore-Tex tube is used to 
direct inferior caval blood to the pulmonary artery, allowing 
systemic venous blood to flow directly and passively to the 
pulmonary circulation. Using an external conduit means minimal 
suturing of the right atrium, a risk factor for late arrhythmias. 
Gore-Tex _ ~ ~__ 
conduit 
Right atrium 
closed 
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Figure S2.2 Diagram showing the site of the right ventriculotomy made during 
the operative repair of truncus arteriosus. This ventriculotomy was 
the source of the biopsy material and more importantly, permits the 
establishment of right ventricle to pulmonary artery continuity 
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Table S4.1 Stem cell characteristics 
Number and viability 
Number of mononuclear cells 
(x 108) 
Number of Lin" cells (x 106) 
Post-thaw viability (%) 
Surface markers 
CD45+ (%) 
absolute cell number x 106 
CD45- (%) 
absolute cell number x105 
CD34+ (%) 
absolute cell number x 106 
CD34- (%) 
6 
absolute cell number x 10 
CD34+ I CD45+ (%) 
absolute cell number x 106 
Group 2 
eBSe Injection 
(n = 6) 
3.1 ± 1.7 (2.9) 
4.7 ± 1.1 (4.4) 
94 ± 2.5 (95) 
92 ± 2.5 (91) 
4.5 ± 0.87 (4.1) 
7.7 ± 3.4 (8.5) 
3.9 ± 2.5 (3.5) 
59 ±8 (56) 
2.8 ± 0.5 (2.9) 
41 ±8 (45) 
2.0 ± 0.8 (1.8) 
62 ± 12 (57) 
2.9 ± 0.5 (2.9) 
Group 4 
PAB &eBSe 
(n = 8) 
3.4 ± 1.5 (3.6) 
4.7 ± 1.0 (4.8) 
94±2.1 (94) 
94±3.1 (94) 
4.3 ± 0.93 (4.2) 
6.1 ± 2.5 (6.7) 
2.7 ± 1.6 (2.5) 
57 ± 11 (58) 
2.6 ± 0.6 (2.8) 
43 ± 11 (42) 
2.1 ± 0.9 (1.9) 
57 ± 11 (58) 
2.6 ± 0.6 (2.8) 
P 
t test 
0.72 
0.88 
0.93 
0.11 
0.72 
0.32 
0.29 
0.63 
0.53 
0.63 
0.83 
0.42 
0.25 
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CD34+ / CD33+ / CD38+ (%) 
absolute cell number x 106 
CD34+ / CD33- / CD38- (%) 
absolute cell number x 106 
CD34- / CD45+ (%) 
absolute cell number x 106 
CD34- / CD45- (%) 
absolute cell number x105 
Group 2 
eBSe Injection 
(n =6) 
36 ± 22 (41) 
1.8±1.3(1.7) 
31 ± 27 (17) 
1.4 ± 1.1 (0.9) 
37 ± 12 (34) 
1.7 ± 0.6 (1.5) 
7.1 ± 3.1 (6.5) 
3.7 ± 2.4 (3.1) 
All data expressed as mean ± SO (median) 
Group 4 
PAB BceBSe 
(n = 8) 
37 ± 17 (47) 
1.7 ± 0.9 (1.8) 
37 ± 17 (47) 
1.2 ± 1.1 (0.7) 
39 ± 11 (38) 
1.8 ± 0.8 (1.6) 
6.3 ± 5.6 (4.8) 
2.9 ± 2.4 (2.2) 
% shown is percentage of lineage negative population 
P 
t test 
0.91 
0.89 
0.70 
0.68 
0.80 
0.80 
0.74 
0.54 
161 
6.1 peR primers 
Human B-2 microglobulin 
Forward/Sense: 5'-GTGTCTGGGTTTCATCAATC-3' 
Reversel Antisense: 5'-GGCAGGCATACTCATCTTTT-3' 
B-actin 
Forward/Sense: 5'-CGGGACCTGACTGACTAC-3' 
Reversel Antisense: 5'-GAAGGAAGGCTGGAAGAG-3' 
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6.2 Haemodynamic data acquisition and analysis 
The pressure-volume catheter was used in conjunction with a pressure signal 
amplifier (Millar Instruments, Houston, Texas, USA) and signal conditioner 
(Leycom Sigma 5/DF, CardioDynamics, Zoetermeer, The Netherlands). A 
perivascular ultrasonic flow probe (Transonics, Ithaca, NY, USA) placed around 
the pulmonary artery just distal to the pulmonary valve was used to give 
simultaneous cardiac output (Figure S1). 
Figure 54.1 Diagram of operative set up 
Pressure-volume 
catheter inserted 
into RV 
-
Flow probe 
placed around 
pulmonary artery 
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Right ventricular pressures and volumes, maximal slopes of systolic pressure 
increment (dP/dtMax) and diastolic decrement (dP/dtMin) and relaxation time 
constant (tau ; exponential fit method) were calculated using customised 
software. 
Figure S4.2 Diagram of pulmonary artery banding, demonstrating reduction of 
cross-sectional area by 30% 
Polyester band around PA 
reduces cross-sectional 
area by 30% 
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Right ventricular systolic and diastolic functional indices were also obtained 
during transient occlusions of the inferior vena cava to reduce preload. Systolic 
contractile indices included the slope and volume-axis intercept of the linear 
end-systolic pressure volume relationship (End-systolic elastance); preload-
recruitable stroke work (PRSW), the slope of the relationship between stroke 
work and end-diastolic volume; and the quadratically modelled end-diastolic 
pressure volume relationship (dP/dtMax-EDV). Diastolic indices included the end-
diastolic pressure volume relationship, tau and dP/dtMin, as described above. 
Figure 54.3 Pressure-volume loops following occlusion of inferior vena cava 
with demonstration of end-systolic pressure volume relationship 
(ESPVR) and end-diastolic pressure-volume relationship 
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Parallel conductance of the right ventricle was evaluated by using injections of 
hypertonic saline solution into the right atrium; slope factor was determined 
using cardiac output to allow for correction of volume measurements at post-hoc 
analysis. Linear modelling was found to be adequate over the range of 
pressures experienced within the right ventricle. Intraclass correlation of 
quadratic versus linear modelling of ESPVR regression during preload reduction 
was assessed using 386 data sets by one-way analysis of variance. 0.989; [95% 
CI 0.979 to 0.999] 
6.3 Immunohistochemistry & laser scanning 
confocal microscopy 
Slides were examined using an Olympus IX70 fluorescent inverted microscope 
(Olympus Corp., Tokyo, Japan) and a Leica TCS SP2 SE laser scanning 
confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany). Negative 
controls were used to calibrate laser power and detector gain settings and 
control for autofluorescence. 
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Table S4.2 Summary table of Invasive haemodynamic measurements 
Group 
Cardiac output 
(I/min) 
Cardiac index 
(I/minlkg) 
Baseline 
One month 
End diastolic volume 
(ml) 
End systolic volume 
(ml) 
Stroke volume 
(ml) 
Stroke work 
(mmHg.ml) 
1 2 3 4 
Control CBSC PAB PAB& CBSC 
1.6 ± 0.3 1.6 ± 0.5 1.6 ± 0.4 1.6 ± 0.2 
2.3 ±0.4 2.3 ±0.3 2.3 ±0.4 2.3±O.4 
0.24 ±0.04 0.27 ±0.07 0.26 ±0.07 0.26 ±0.06 
0.19 ±0.04 0.2 ±0.02 0.21 ±0.04 0.22 ±0.06 
16.2 ± 5.2 15.0 ±4.7 16.3 ± 4.1 17.2±2.9 
32.1 ±6.3 31.8 ±4.9 27.9 ±6.6 29.4 ± 7.0 
7.9 ±2.3 7.7 ±2.2 8.2 ± 1.1 8.1 ± 1.5 
16.2 ±3.1 15.7 ± 2.0 18.6 ± 3.6 17.7 ± 4.5 
8.4 ± 1.0 8.5 ± 1.2 8.2 ± 1.3 8.4 ± 1.8 
15.9 ± 2.0 15.9 ± 2.7 14.6 ± 2.2 14.6 ± 2.0 
120.7 ± 16.5 126.6 ± 33.0 125.2 ± 33.5 128.2 ± 20.3 
257.1 ± 32.8 249.8 ± 26.9 445.8 ± 73.9 465.4 ± 90.6 
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Group 
End diastolic pressure 
(mmHg) 
End systolic pressure 
(mmHg) 
dPdtMax 
(mmHg/s) 
dPdtMin 
(mmHg/s) 
1 
Control 
5.5 % 1.8 
3.8 %2.6 
19.3 % 1.9 
14.9 % 2.4 
2 
CBSC 
5.9%4.5 
3.1 %2.3 
19.6 % 5.0 
14.8 %2.1 
3 
PAB 
5.9 %3.9 
6.7 %2.7 
20.7 % 2.5 
41.7 % 6.9 
4 
PAB&CBSC 
6.0 %2.4 
6.5 %2.4 
20.3 %2.9 
41.0 % 6.8 
461.2 % 61.8 471.3 % 42.6 461.0 % 53.0 460.0 % 64.0 
412.8 % 39.1 427.3 % 33.1 632.3 % 86.2 673.3 % 97.5 
317.3 % 33.9 322.7 % 43.6 333.9 % 56.3 337.9 % 34.7 
271.2 % 21.7 276.8 % 27.8 585.3 % 93.7 606.1 % 93.8 
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Group 
tau 
(ms) 
Diastolic stiffness constant 
(k) 
Ees slope 
PRSW slope 
dPdtmax-EDV slope 
All values mean ± SO 
1 
Control 
36.1 ± 3.8 
31.3 ± 2.8 
0.23 ±0.06 
0.16 ± 0.03 
1.11 ± 0.07 
1.04 ± 0.05 
10.9 ± 0.8 
10.6 % 1.4 
12.7 ± 4.2 
10.3 % 3.4 
2 
CBSC 
36.0 ± 7.9 
30.6 ±2.6 
0.23 ±0.04 
0.16 ± 0.02 
1.11 % 0.11 
1.10 %0.11 
11.3 % 1.0 
11.0 ± 1.6 
12.S ± 3.4 
10.3 ±3.1 
3 
PAB 
3S.2 ±8.S 
48.4 ±3.9 
0.23 ±O.OS 
0.28 ±O.OS 
1.18 % 0.11 
2.20 ± 0.18 
11.7 % 1.4 
27.5 ±3.3 
13.3 ± 2.6 
2S.3 ±4.S 
4 
PAB&CBSC 
3S.0 ± 4.7 
43.7 ± 3.4 
0.24 ±O.OS 
0.2S ±0.03 
1.09 ± 0.13 
2.70 ± 0.16 
11.3 % 2.0 
32.2 ±3.8 
11.9 ± 2.1 
29.6 ±4.3 
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Table S4.3 Summary morphometric data 
Age Baseline 
(days) 
One month 
Body Baseline 
weight 
(kg) One month 
Placebo 
(n=6) 
10.8 ± 3.0 
43.8 ±6.3 
6.8 ±0.7 
10.9 ± 1.5 
Cells 
(n=6) 
9.0 ± 1.7 
43.2 ±3.7 
6.0 ±0.2 
11.0 ± 0.9 
Band 
(n=8) 
10.9 ± 2.8 
43.6 ±6.2 
6.1 ±0.9 
11.1 ± 1.0 
Total heart weight 64.0 ± 8.4 (62.0) 64.2 ± 10.2 (62.0) 83.9 ± 16.6 (82.0) 
(g) 
Heart to body 
weight index 
(glkg) 
RV weight 
(g) 
RV to body 
weight index 
(g/l<g) 
6.1 ± 0.7 (6.0) 
11.1 ± 1.4 (11.0) 
1.1 ± 0.2 (1.1) 
5.8 ± 0.6 (5.9) 6.5 ± 1.3 (5.9) 
11.3 ± 1.5 (11.0) 15.6 ± 3.1 (15.0) 
1.0 ± 0.1 (1.0) 1.4 ± 0.6 (1.3) 
Band & cells P 
(n=8) 
10.6 ± 2.1 NS 
44.8 ±6.0 NS 
7.2 ± 1.2 NS 
12.5 ±2.4 NS 
90.0 ± 17.0 (84.5)* <0.05 
6.5 ± 0.8 (6.5) NS 
18.1 ± 4.4 (18.0)*t <0.05 
1.4 :i: 0.3 (1.3) NS 
170 
Placebo Cells Band Band & cells p 
(n=6) (n=6) (n=8) (n=8) 
RV thickness 4.5 :t: 0.5 (4.5) 4.5 :t: 0.8 (4.0) 5.9 :t: 0.6 (6.0)*t 6.2 :t: 0.9 (6.0)* <0.05 
(mm) 
LV thickness 9.2 :t: 0.7 (9.3) 9.6 :t 0.8 (9.5) 8.9 :t 1.1 (9.0) 9.4 :t 0.7 (9.5) NS 
(mm) 
RV:LV thickness 
0.50:t 0.08 
(0.49) 0.47 :t: 0.11 (0.46) 0.67 :t 0.05 (0.46)*t 0.66 :t 0.09 (0.68)* <0.05 
ratio 
Mean ± SO (range) 
One-way ANOVA or Kruskal Wallis with Tukey or Dunns post-testing, as 
appropriate 
* versus Placebo 
t versus Cells 
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